celecoxib has been researched along with Ache in 183 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "NAXOZOL was not inferior to celecoxib in protecting the gastrointestinal tract and providing pain relief in patients with osteoarthritis." | 9.34 | A comparative study of the efficacy of NAXOZOL compared to celecoxib in patients with osteoarthritis. ( Kang, CN; Kim, HJ; Kim, JH; Lee, S; Lee, WS; Moon, SH; Park, MS; Shin, SJ, 2020) |
| "Celecoxib was unable to prevent oxaliplatin-related vascular pain in this study." | 9.30 | Randomized phase II trial of the prophylactic use of celecoxib for the prevention of oxaliplatin-related peripheral vascular pain in Capeox (YCOG1205). ( Endo, I; Ishibe, A; Momiyama, M; Nagamine, K; Ota, M; Saigusa, Y; Saito, S; Suwa, H; Suwa, Y; Suzuki, S; Watanabe, J; Watanabe, K; Yamanaka, T, 2019) |
| "To evaluate the effectiveness of celecoxib for pain relief and antipyresis during second trimester abortion using sublingual misoprostol." | 9.27 | Effectiveness of celecoxib for pain relief and antipyresis in second trimester medical abortions with misoprostol: a randomized controlled trial. ( Choobun, T; Tintara, H; Voradithi, P, 2018) |
| "The purpose of this randomized, placebo-controlled, double-blind study was to investigate the preventive effect of oral administration of celecoxib (CLX) on the acute radiation- induced skin toxicity in patients with breast cancer." | 9.27 | Randomized Double-blind Placebo-controlled Trial of Celecoxib for the Prevention of Skin Toxicity in Patients Receiving Radiation Therapy for Breast Cancer. ( Danesh, B; Ghasemi, A; Hosseinimehr, SJ; Yazdani-Charati, J, 2018) |
| "To further characterize time-to-first pain relief, effect size, correlations between various outcome measures and durability of relief for single-tablet naproxen 500 mg/esomeprazole 20 mg (NAP/ESO) given twice daily and celecoxib (CEL) (200 mg) given once daily versus placebo in knee osteoarthritis (OA)." | 9.20 | Onset and durability of pain relief in knee osteoarthritis: Pooled results from two placebo trials of naproxen/esomeprazole combination and celecoxib. ( Bello, AE; Fort, JG; Grahn, AY; Holt, RJ; Kent, JD, 2015) |
| "To assess the efficacy and safety of 12-week treatment with ketoprofen in ultradeformable phospholipid vesicles in patients with OA knee pain and to compare the efficacy with that of ketoprofen-free vehicle and celecoxib." | 9.17 | A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in Transfersome gel (IDEA-033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with osteoarthritis. ( Bolten, W; Cevc, G; Conaghan, PG; Dickson, J; Rother, M, 2013) |
| "The objective of this study was to compare the efficacy and tolerability of celecoxib, meloxicam and paracetamol in late Kashin-Beck disease." | 9.15 | Efficacy of celecoxib, meloxicam and paracetamol in elderly Kashin-Beck disease (KBD) patients. ( Kang, P; Li, J; Liu, G; Liu, W; Luo, R; Ma, X; Pei, F; Shen, B; Xie, Q; Zhou, Z, 2011) |
| "The sore throat pain model was used to evaluate single-dose effects of celecoxib 50 and 100 mg over 6 hours in the treatment of acute pharyngeal pain." | 9.15 | Efficacy of low-dose celecoxib in patients with acute pain. ( Berger, M; McCabe, D; Rizouk, J; Sanner, KM; Savino, L; Schachtel, BP; Schachtel, EP; Zhang, R, 2011) |
| "Randomized clinical trials evaluating ultramicronised diclofenac, diclofenac, celecoxib, etodolac and placebo in patients with osteoarthritis were identified." | 9.12 | Efficacy of ultramicronised diclofenac in patients with osteoarthritis - systematic review with network meta-analysis. ( Auletta, LL; de Almeida Macedo, E; de Campos, GC; Kummer, AM; Millan Fachi, M; Papaleo Rosim, M, 2021) |
| "To evaluate the efficacy and upper gastrointestinal (UGI) safety of celecoxib, compared with nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs), among patients with osteoarthritis." | 9.12 | Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. ( Agrawal, NM; Andrade-Ortega, L; Bello, AE; Eisen, GM; Fort, JG; Goldstein, JL; Hanrahan, PS; Levy, RA; Singh, G; Stenson, WF; Triadafilopoulos, G; Wallemark, C, 2006) |
| " The multicenter, double-blind, placebo- and celecoxib-controlled Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) evaluated their efficacy and safety as a treatment for knee pain from osteoarthritis." | 9.12 | Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. ( Bingham, CO; Bradley, JD; Brandt, KD; Clegg, DO; Cush, JJ; Furst, DE; Harris, CL; Hooper, MM; Jackson, CG; Klein, MA; Lane, NE; Molitor, JA; Moreland, LW; Moskowitz, RW; O'Dell, JR; Oddis, CV; Reda, DJ; Sawitzke, AD; Schnitzer, TJ; Schumacher, HR; Shi, H; Weisman, MH; Williams, HJ; Wolfe, F; Yocum, DE, 2006) |
| "COX-2 activation may mediate capecitabine induced toxicities, eg, hand-foot syndrome (HFS) and colorectal cancer progression, both of which may be improved by concurrent celecoxib." | 9.12 | Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? ( Ayers, GD; Brown, T; Crane, CC; Curley, SA; Delcos, M; Feig, B; Janjan, N; Lin, EH; Morris, J; Rodriguez-Bigas, MA; Ross, A; Skibber, J; Vadhan, SR, 2006) |
| "The aim of this study was to compare the pain relief and tolerability of SKI306X and celecoxib in patients with RA." | 9.12 | Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial. ( Baek, HJ; Cha, HS; Jung, HG; Kang, SW; Kim, HA; Koh, EM; Lee, CK; Lee, EY; Lee, YJ; Song, YW; Suh, Y; Yoo, B, 2007) |
| "5 mg/acetaminophen 325 mg combination tablets (tramadol/APAP) as add-on therapy for subjects with osteoarthritis (OA) pain inadequately controlled by COX-2 nonsteroidal antiinflammatory drugs (NSAID)." | 9.11 | Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. ( Emkey, R; Jordan, D; Kamin, M; Rosenthal, N; Wu, SC, 2004) |
| "Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor used to treat pain." | 9.10 | A randomized, clinical trial comparing oral celecoxib 200 mg, celecoxib 400 mg, and ibuprofen 600 mg for acute pain. ( Goldberg, J; Kenwood, A; Lavery, R; Salo, DF; Shapiro, T; Varma, V, 2003) |
| "An open-label multicentre study was conducted in primary care centres in Spain to investigate the effect of a switch from celecoxib to rofecoxib among patients with osteoarthritis and to identify factors associated with a good response to rofecoxib treatment." | 9.10 | Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. ( Collantes-Estevez, E; Fernandez-Perez, C, 2003) |
| "The present data confirm our previous observations in patients with rheumatoid arthritis, further suggesting that nimesulide represents an effective agent for the treatment of joint pain, with particular reference to the rapid onset of its analgesic effect." | 9.10 | A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. ( Bianchi, M; Broggini, M, 2003) |
| " Celecoxib, an anti-inflammatory and analgesic agent indicated for the treatment of osteoarthritis and rheumatoid arthritis, is the first cyclooxygenase (COX) inhibitor with well-defined cyclooxygenase-2 (COX-2) specificity." | 8.80 | Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results. ( Tindall, E, 1999) |
| "Celecoxib is the first COX-2 specific inhibitor approved for use in osteoarthritis and rheumatoid arthritis." | 8.80 | Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. ( Clemett, D; Goa, KL, 2000) |
| "The non-steroidal anti-inflammatory drug celecoxib has long been used for reducing pain, in spite of moderate gastrointestinal side effects." | 7.85 | The Analgesic Effects of Celecoxib on the Formalin-induced Short- and Long-term Inflammatory Pain. ( Guo, XJ; Liang, JC; Sun, Y; Tang, K; Wang, HY; Wang, Y; Wang, YT; Yin, JB; Zhao, YQ, 2017) |
| " Compared with celecoxib controls, both oral and IA, ropivacaine IA treatment resulted in a significant reduction of pain upon successive PGPS reactivation, as demonstrated in two different pain models, gait analysis and incapacitance testing." | 7.81 | Intra-articular (IA) ropivacaine microparticle suspensions reduce pain, inflammation, cytokine, and substance p levels significantly more than oral or IA celecoxib in a rat model of arthritis. ( Balla, K; Bendele, A; Bogseth, R; Gass, J; Graham, S; Hutchcraft, A; Rabinow, B; Valaitis, P; Werling, J, 2015) |
| "To test the efficacy of an animal model of pain and stress and evaluate the effects of celecoxib administered when orthodontic force is applied." | 7.75 | Effect of celecoxib on emotional stress and pain-related behaviors evoked by experimental tooth movement in the rat. ( Gonzales, C; Hotokezaka, H; Koga, Y; Shibazaki, T; Yoshida, N; Yozgatian, JH; Zeredo, JL, 2009) |
| " This study was undertaken to apply the diffusion of innovations theory to the prescribing of celecoxib and to determine if prescriber and patient characteristics differed amongst early use of celecoxib for acute pain versus chronic musculoskeletal conditions." | 7.74 | Use of celecoxib immediately post marketing in Canada: acute or chronic pain? ( Kozyrskyj, AL; Racher, A; Raymond, C, 2007) |
| "The purpose of this study is to clarify involvement ratios between central and peripheral cyclooxygenase (COX)-2 in rat inflammatory pain models, by evaluating celecoxib and [6-chloro-2-(4-chlorobenzoyl)-1H-indol-3-yl]acetic acid (CIAA) on carrageenan-induced mechanical and thermal hyperalgesia." | 7.74 | Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA. ( Kita, Y; Murata, Y; Okumura, T; Sakakibara, A, 2008) |
| " Low solubility and bioavailability issues related with celecoxib lead to the development and advancement in the discovery and research of some possible formulation administered either orally, topically or via transdermal route." | 6.66 | A journey of celecoxib from pain to cancer. ( Purohit, P; Saxena, P; Sharma, PK, 2020) |
| "Patients with osteoarthritis are often affected by a number of cardiovascular comorbidities, including hypertension, which is present in about 40% of cases." | 6.58 | Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain. ( Angeli, F; Reboldi, G; Signorotti, S; Trapasso, M; Verdecchia, P, 2018) |
| "The preemptive analgesia regimen of pregabalin combined with celecoxib had positive effects on improving acute pain and reducing the cumulative dose of opioids after TKA." | 5.69 | Positive Preemptive Analgesia Effectiveness of Pregabalin Combined with Celecoxib in Total Knee Arthroplasty: A Prospective Controlled Randomized Study. ( Ding, C; Liu, X; Xiang, B; Yan, L; Zhou, Y, 2023) |
| "Acupuncture treatment, celecoxib, and placebo medication have different modulation effects on vlPAG DPMS in KOA knee pain patients." | 5.69 | Modulation effects of different treatments on periaqueductal gray resting state functional connectivity in knee osteoarthritis knee pain patients. ( Chen, Y; Cheng, S; Dong, X; He, W; Hu, S; Jiang, N; Li, X; Li, Z; Liang, F; Sun, N; Sun, R; Tang, C; Wintermark, M; Yang, W; Zeng, F; Zhang, X; Zhou, J; Zhou, Y, 2023) |
| "Metformin was administered orally every day to rats with OA." | 5.62 | Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy-Lysosomal Pathway. ( Cho, KH; Cho, ML; Choi, JW; Jung, K; Kim, SJ; Kwon, JY; Lee, AR; Lee, DH; Lee, SH; Lee, SY; Min, HK; Na, HS; Park, SH; Woo, JS, 2021) |
| "Kartogenin (KGN) is a small drug-like molecule that induces chondrogenesis in mesenchymal stem cells (MSCs)." | 5.48 | Kartogenin inhibits pain behavior, chondrocyte inflammation, and attenuates osteoarthritis progression in mice through induction of IL-10. ( Cho, KH; Cho, ML; Choi, J; Jung, K; Kim, SJ; Kwon, JY; Lee, CY; Lee, SH; Na, HS; Park, SH; Shin, DY, 2018) |
| " Dose-dependent cardiac toxicity limits long-term use of celecoxib." | 5.42 | The cancer pain related factors affected by celecoxib together with cetuximab in head and neck squamous cell carcinoma. ( Chen, Z; Hu, R; Huang, Y; Jiang, H; Jiang, J; Xu, H; Yan, J; Yang, Y; Zhang, Y, 2015) |
| " Indomethacin was superior to celecoxib for pain score at rest at 8-12 h and celecoxib + parecoxib, diclofenac, and ketorolac for pain score on movement at 48 h." | 5.41 | Comparison of different nonsteroidal anti-inflammatory drugs for cesarean section: a systematic review and network meta-analysis. ( Blake, L; Carvalho, B; Carver, AL; Desai, N; Murdoch, I; O'Carroll, JE; Onwochei, DN; Sultan, P, 2023) |
| "Pain is the most common complaint in the medical field and the identification of novel compounds that can effectively treat painful states without causing side effects remains a major challenge in biomedical research." | 5.40 | Antinociceptive effect of 3-(4-fluorophenyl)-5-trifluoromethyl-1H-1-tosylpyrazole. A Celecoxib structural analog in models of pathological pain. ( Bonacorso, HG; Correa, MS; Ferreira, J; Oliveira, SM; Otuki, MF; Paim, GR; Prudente, AS; Silva, CR; Wentz, AP, 2014) |
| "Intra-articular PRP is significantly better than celecoxib in improving pain, function and stiffness in early knee OA." | 5.34 | Clinical comparison of platelet-rich plasma injection and daily celecoxib administration in the treatment of early knee osteoarthritis: A randomized clinical trial. ( Cruz-Santiago, L; Garcia-Cruz, CR; Lugo-Radillo, A; Mendoza-Cano, O; Reyes-Sosa, R, 2020) |
| "NAXOZOL was not inferior to celecoxib in protecting the gastrointestinal tract and providing pain relief in patients with osteoarthritis." | 5.34 | A comparative study of the efficacy of NAXOZOL compared to celecoxib in patients with osteoarthritis. ( Kang, CN; Kim, HJ; Kim, JH; Lee, S; Lee, WS; Moon, SH; Park, MS; Shin, SJ, 2020) |
| "Celecoxib was unable to prevent oxaliplatin-related vascular pain in this study." | 5.30 | Randomized phase II trial of the prophylactic use of celecoxib for the prevention of oxaliplatin-related peripheral vascular pain in Capeox (YCOG1205). ( Endo, I; Ishibe, A; Momiyama, M; Nagamine, K; Ota, M; Saigusa, Y; Saito, S; Suwa, H; Suwa, Y; Suzuki, S; Watanabe, J; Watanabe, K; Yamanaka, T, 2019) |
| "To evaluate the effectiveness of celecoxib for pain relief and antipyresis during second trimester abortion using sublingual misoprostol." | 5.27 | Effectiveness of celecoxib for pain relief and antipyresis in second trimester medical abortions with misoprostol: a randomized controlled trial. ( Choobun, T; Tintara, H; Voradithi, P, 2018) |
| "The purpose of this randomized, placebo-controlled, double-blind study was to investigate the preventive effect of oral administration of celecoxib (CLX) on the acute radiation- induced skin toxicity in patients with breast cancer." | 5.27 | Randomized Double-blind Placebo-controlled Trial of Celecoxib for the Prevention of Skin Toxicity in Patients Receiving Radiation Therapy for Breast Cancer. ( Danesh, B; Ghasemi, A; Hosseinimehr, SJ; Yazdani-Charati, J, 2018) |
| "In a multicenter, double-blind, placebo- and celecoxib-controlled trial, patients with moderate to severe OA pain were randomized to placebo; celecoxib 200 mg daily for 16 weeks; or galcanezumab 5, 50, 120, and 300 mg subcutaneously every 4 weeks, twice." | 5.27 | CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial. ( Brown, R; Camporeale, A; de la Peña, A; Deeg, MA; Jin, Y; Kivitz, AJ; McNearney, TA; Monteith, D; Raddad, E; Schnitzer, TJ; Smith, C; Xiao, N, 2018) |
| "This experimental, translational, experimental pain, single-center, randomized, double-blind, single-dose, 3-treatment, 3-period cross-over proof-of-concept volunteer trial studied the efficacy of a novel TRPV1 antagonist (V116517) on capsaicin- and UV-B-induced hyperalgesia." | 5.22 | A randomized, double-blind, positive-controlled, 3-way cross-over human experimental pain study of a TRPV1 antagonist (V116517) in healthy volunteers and comparison with preclinical profile. ( Arendt-Nielsen, L; Harris, S; Hummel, M; Kapil, R; Knappenberger, T; Kyle, D; O'Keefe, S; Whiteside, GT, 2016) |
| "To further characterize time-to-first pain relief, effect size, correlations between various outcome measures and durability of relief for single-tablet naproxen 500 mg/esomeprazole 20 mg (NAP/ESO) given twice daily and celecoxib (CEL) (200 mg) given once daily versus placebo in knee osteoarthritis (OA)." | 5.20 | Onset and durability of pain relief in knee osteoarthritis: Pooled results from two placebo trials of naproxen/esomeprazole combination and celecoxib. ( Bello, AE; Fort, JG; Grahn, AY; Holt, RJ; Kent, JD, 2015) |
| "To assess the efficacy and safety of 12-week treatment with ketoprofen in ultradeformable phospholipid vesicles in patients with OA knee pain and to compare the efficacy with that of ketoprofen-free vehicle and celecoxib." | 5.17 | A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in Transfersome gel (IDEA-033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with osteoarthritis. ( Bolten, W; Cevc, G; Conaghan, PG; Dickson, J; Rother, M, 2013) |
| "This 12-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging trial evaluated tramadol ER (extended-release tramadol) in the management of osteoarthritis pain." | 5.15 | Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: a double-blind, randomized, dose-ranging trial. ( Benson, C; DeLemos, BP; Fleming, B; Gana, TJ; Pascual, ML; Rosanna, R; Xiang, J, 2011) |
| "The objective of this study was to compare the efficacy and tolerability of celecoxib, meloxicam and paracetamol in late Kashin-Beck disease." | 5.15 | Efficacy of celecoxib, meloxicam and paracetamol in elderly Kashin-Beck disease (KBD) patients. ( Kang, P; Li, J; Liu, G; Liu, W; Luo, R; Ma, X; Pei, F; Shen, B; Xie, Q; Zhou, Z, 2011) |
| "The sore throat pain model was used to evaluate single-dose effects of celecoxib 50 and 100 mg over 6 hours in the treatment of acute pharyngeal pain." | 5.15 | Efficacy of low-dose celecoxib in patients with acute pain. ( Berger, M; McCabe, D; Rizouk, J; Sanner, KM; Savino, L; Schachtel, BP; Schachtel, EP; Zhang, R, 2011) |
| "Randomized clinical trials evaluating ultramicronised diclofenac, diclofenac, celecoxib, etodolac and placebo in patients with osteoarthritis were identified." | 5.12 | Efficacy of ultramicronised diclofenac in patients with osteoarthritis - systematic review with network meta-analysis. ( Auletta, LL; de Almeida Macedo, E; de Campos, GC; Kummer, AM; Millan Fachi, M; Papaleo Rosim, M, 2021) |
| " The meta-analysis indicated that celecoxib reduced pain more effectively than diclofenac sodium in patients with KOA, as evaluated by the VAS score." | 5.12 | Meta-analysis Comparing Celecoxib with Diclofenac Sodium in Patients with Knee Osteoarthritis. ( Hou, S; Huang, H; Liang, G; Liang, H; Liu, J; Luo, M; Pan, J; Yang, W; Zeng, L; Zhao, J, 2021) |
| "To evaluate the efficacy and upper gastrointestinal (UGI) safety of celecoxib, compared with nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs), among patients with osteoarthritis." | 5.12 | Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. ( Agrawal, NM; Andrade-Ortega, L; Bello, AE; Eisen, GM; Fort, JG; Goldstein, JL; Hanrahan, PS; Levy, RA; Singh, G; Stenson, WF; Triadafilopoulos, G; Wallemark, C, 2006) |
| " The multicenter, double-blind, placebo- and celecoxib-controlled Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) evaluated their efficacy and safety as a treatment for knee pain from osteoarthritis." | 5.12 | Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. ( Bingham, CO; Bradley, JD; Brandt, KD; Clegg, DO; Cush, JJ; Furst, DE; Harris, CL; Hooper, MM; Jackson, CG; Klein, MA; Lane, NE; Molitor, JA; Moreland, LW; Moskowitz, RW; O'Dell, JR; Oddis, CV; Reda, DJ; Sawitzke, AD; Schnitzer, TJ; Schumacher, HR; Shi, H; Weisman, MH; Williams, HJ; Wolfe, F; Yocum, DE, 2006) |
| "COX-2 activation may mediate capecitabine induced toxicities, eg, hand-foot syndrome (HFS) and colorectal cancer progression, both of which may be improved by concurrent celecoxib." | 5.12 | Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? ( Ayers, GD; Brown, T; Crane, CC; Curley, SA; Delcos, M; Feig, B; Janjan, N; Lin, EH; Morris, J; Rodriguez-Bigas, MA; Ross, A; Skibber, J; Vadhan, SR, 2006) |
| "The aim of this study was to compare the pain relief and tolerability of SKI306X and celecoxib in patients with RA." | 5.12 | Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial. ( Baek, HJ; Cha, HS; Jung, HG; Kang, SW; Kim, HA; Koh, EM; Lee, CK; Lee, EY; Lee, YJ; Song, YW; Suh, Y; Yoo, B, 2007) |
| "5 mg/acetaminophen 325 mg combination tablets (tramadol/APAP) as add-on therapy for subjects with osteoarthritis (OA) pain inadequately controlled by COX-2 nonsteroidal antiinflammatory drugs (NSAID)." | 5.11 | Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. ( Emkey, R; Jordan, D; Kamin, M; Rosenthal, N; Wu, SC, 2004) |
| " In well designed clinical trials of 1-52 weeks' duration in patients with osteoarthritis (OA) or rheumatoid arthritis, the efficacy of oral lumiracoxib 100-400 mg/day in decreasing pain intensity and improving functional status was greater than that with placebo and similar to those with nonselective NSAIDs or celecoxib 200mg once daily." | 5.11 | Lumiracoxib. ( Curran, MP; Lyseng-Williamson, KA, 2004) |
| "Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor used to treat pain." | 5.10 | A randomized, clinical trial comparing oral celecoxib 200 mg, celecoxib 400 mg, and ibuprofen 600 mg for acute pain. ( Goldberg, J; Kenwood, A; Lavery, R; Salo, DF; Shapiro, T; Varma, V, 2003) |
| "An open-label multicentre study was conducted in primary care centres in Spain to investigate the effect of a switch from celecoxib to rofecoxib among patients with osteoarthritis and to identify factors associated with a good response to rofecoxib treatment." | 5.10 | Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. ( Collantes-Estevez, E; Fernandez-Perez, C, 2003) |
| "The present data confirm our previous observations in patients with rheumatoid arthritis, further suggesting that nimesulide represents an effective agent for the treatment of joint pain, with particular reference to the rapid onset of its analgesic effect." | 5.10 | A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. ( Bianchi, M; Broggini, M, 2003) |
| "CTC may provide a relevant addition to pain therapy due to its: i) unique co-crystal structure conferring differentiated intrinsic dissolution profiles on constituent APIs, ii) modified clinical pharmacokinetics (slower absorption of tramadol and faster absorption of celecoxib) compared with commercially available single-entity reference products (in agreement with modified dissolution rates), iii) superior benefit-risk ratio compared with reference products (suggested by preclinical synergistic antinociceptive effects, without potentiation of adverse effects), and iv) efficacy in a phase 2 trial of moderate to severe pain following extraction of ≥2 impacted third molars requiring bone removal, where CTC doses containing low doses of APIs exerted a significant effect." | 5.01 | Co-crystal of tramadol-celecoxib: preclinical and clinical evaluation of a novel analgesic. ( Almansa, C; Encina, G; Gascon, N; Merlos, M; Miguel Vela, J; Morte, A; Plata-Salamán, C; Smith, K, 2019) |
| " All treatments except acetaminophen showed clinically significant improvement from baseline pain." | 4.91 | Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. ( Bannuru, RR; Kent, DM; McAlindon, TE; Schmid, CH; Vaysbrot, EE; Wong, JB, 2015) |
| "Analysis of randomized controlled trials from the Pfizer clinical trial repository (final study reports completed by 31 July 2011) in which celecoxib was compared with placebo or non-selective non-steroidal anti-inflammatory drugs (nsNSAIDs) for treatment of pain or inflammation in adults." | 4.89 | Safety of celecoxib compared with placebo and non-selective NSAIDs: cumulative meta-analysis of 89 randomized controlled trials. ( Berger, MF; Essex, MN; Park, PW; Upadhyay, S; Zhang, RY, 2013) |
| " Both celecoxib and valdecoxib are indicated for the treatment of primary dysmenorrhea, and may be effective in postoperative pain, including hysterectomy, and pain associated with endometriosis." | 4.81 | COX-2 inhibitors and their role in gynecology. ( Hayes, EC; Rock, JA, 2002) |
| " Thus, physiological and pathophysiological roles of COX-2 were considered from the standpoint of clinical effects of the two latest COX-2 selective inhibitors, celecoxib and rofecoxib, on inflammation, pain, fever and colorectal cancer together with their adverse effects on gastrointestinal, renal and platelet functions; and the usefulness and limits of COX-2-selective inhibitors were discussed with the trends of new NSAIDs development." | 4.81 | [Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors]. ( Nakamura, H, 2001) |
| " Celecoxib, an anti-inflammatory and analgesic agent indicated for the treatment of osteoarthritis and rheumatoid arthritis, is the first cyclooxygenase (COX) inhibitor with well-defined cyclooxygenase-2 (COX-2) specificity." | 4.80 | Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results. ( Tindall, E, 1999) |
| "Celecoxib is the first COX-2 specific inhibitor approved for use in osteoarthritis and rheumatoid arthritis." | 4.80 | Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. ( Clemett, D; Goa, KL, 2000) |
| "Celecoxib is the first COX-2-specific inhibitor approved for relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA), as well as for treatment of familial adenomatous polyposis." | 4.80 | Celecoxib clinical profile. ( Tive, L, 2000) |
| "Celecoxib is a cyclooxygenase- (COX)-1-sparing inhibitor of COX-2 that is indicated for the treatment of osteoarthritis and rheumatoid arthritis." | 4.80 | The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib. ( Geis, GS; Maddrey, WC; Maurath, CJ; Verburg, KM, 2000) |
| " Destabilization of the medial meniscus (DMM) using a mouse model was combined with three approaches: the treatment of celecoxib, capsaicin, and sensory nerve-specific prostaglandin E2 receptor 4 (EP4)-knockout mice." | 4.12 | Inhibition of PGE2 in Subchondral Bone Attenuates Osteoarthritis. ( Cai, M; Ding, Y; Li, H; Li, S; Li, Y; Sun, Q; Xie, W; Zhang, Y, 2022) |
| " The acetylcholinesterase inhibitor (ACHEI); neostigmine, is known clinically for its analgesic effect in the perioperative phases proving high efficacy; besides possessing anti-inflammatory properties controlling immune cells and cytokine level." | 4.02 | The effective interplay of (non-) selective NSAIDs with neostigmine in animal models of analgesia and inflammation. ( Abdel-Bary, A; El-Tahan, RA; Gowayed, MA, 2021) |
| "The aim of this study was to evaluate the effect of vitamin E co-administration with celecoxib in thermal and inflammatory pain in two model of pain assessment including thermal tail flick test of acute pain and formalin induced inflammatory model in adult male rats." | 3.91 | Evidence for antinociceptive effects of combined administration of vitamin E and celecoxib in tail-flick and formalin test in male rats. ( Izadi, G; Sepehri, G; Shamsi Meymandi, M; Zamiri, Z, 2019) |
| "The non-steroidal anti-inflammatory drug celecoxib has long been used for reducing pain, in spite of moderate gastrointestinal side effects." | 3.85 | The Analgesic Effects of Celecoxib on the Formalin-induced Short- and Long-term Inflammatory Pain. ( Guo, XJ; Liang, JC; Sun, Y; Tang, K; Wang, HY; Wang, Y; Wang, YT; Yin, JB; Zhao, YQ, 2017) |
| "In patients with multiple comorbidities, naproxen- and ibuprofen-containing regimens are more effective and cost-effective in managing OA pain than opioids, celecoxib or SOC." | 3.83 | Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities. ( Collins, JE; Hunter, DJ; Jordan, JM; Katz, JN; Losina, E; Paltiel, AD; Smith, SR; Solomon, DH; Suter, LG; Yelin, E, 2016) |
| " Compared with celecoxib controls, both oral and IA, ropivacaine IA treatment resulted in a significant reduction of pain upon successive PGPS reactivation, as demonstrated in two different pain models, gait analysis and incapacitance testing." | 3.81 | Intra-articular (IA) ropivacaine microparticle suspensions reduce pain, inflammation, cytokine, and substance p levels significantly more than oral or IA celecoxib in a rat model of arthritis. ( Balla, K; Bendele, A; Bogseth, R; Gass, J; Graham, S; Hutchcraft, A; Rabinow, B; Valaitis, P; Werling, J, 2015) |
| " These results suggest that ceftriaxone, particularly in combinations with ibuprofen, celecoxib, paracetamol, or levetiracetam, may provide useful approach to the clinical treatment of inflammation-related pain." | 3.80 | Antihyperalgesic/antinociceptive effects of ceftriaxone and its synergistic interactions with different analgesics in inflammatory pain in rodents. ( Boškovic, BD; Kovacevic, JM; Micov, AM; Stepanovic-Petrovic, RM; Tomic, MA, 2014) |
| "In this study we analyzed the mechanisms underlying celecoxib-induced analgesia in a model of inflammatory pain in rats, using the intracerebroventricular (i." | 3.78 | Endogenous opioid and cannabinoid mechanisms are involved in the analgesic effects of celecoxib in the central nervous system. ( Bakhle, YS; Camêlo, VM; Dos Reis, WG; Faraco, A; Francischi, JN; Paiva-Lima, P; Rezende, RM, 2012) |
| "The purpose of this study was to compare the gait parameters recorded on the CatWalk and the mechanical sensitivity with von Frey filaments of two putative models of osteoarthritis over a one month period, and to evaluate the effect of celecoxib on these parameters." | 3.77 | Gait analysis and pain response of two rodent models of osteoarthritis. ( Beaudry, F; Ferland, CE; Laverty, S; Vachon, P, 2011) |
| " This study was undertaken to determine the nature of the interaction between codeine and celecoxib or etoricoxib in peritoneal irritation-induced visceral pain in mice." | 3.77 | Codeine did not increase analgesic efficacy of coxibs in contrast to that of paracetamol or ibuprofen: isobolographic analysis in mice. ( Janovsky, M; Krsiak, M, 2011) |
| " First, validate PEAP with Complete Freund's Adjuvant (CFA)-induced inflammation for the assessment of the affective component of pain using the reference analgesics celecoxib, diclofenac and duloxetine; fluoxetine and scopolamine were tested as negative controls." | 3.76 | Comparison of mechanical allodynia and the affective component of inflammatory pain in rats. ( Baker, SJ; Boyce-Rustay, JM; Decker, MW; Honore, P; Kohnken, R; Simler, GH; Wensink, EJ; Zhong, C, 2010) |
| ") were assessed using acetic acid-induced vascular permeability, carrageenan-induced paw edema, and croton oil-induced ear edema." | 3.76 | The analgesic and anti-inflammatory effect of WIN-34B, a new herbal formula for osteoarthritis composed of Lonicera japonica Thunb and Anemarrhena asphodeloides BUNGE in vivo. ( Cho, YB; Hur, J; Jung, I; Jung, KC; Kang, JY; Kang, M; Kim, KS; Kim, SH; Lee, JD; Lee, JH; Park, DS; Yoo, MC, 2010) |
| "To test the efficacy of an animal model of pain and stress and evaluate the effects of celecoxib administered when orthodontic force is applied." | 3.75 | Effect of celecoxib on emotional stress and pain-related behaviors evoked by experimental tooth movement in the rat. ( Gonzales, C; Hotokezaka, H; Koga, Y; Shibazaki, T; Yoshida, N; Yozgatian, JH; Zeredo, JL, 2009) |
| "A model of visceral pain consisting of intraperitoneal injection of acetic acid (writhing test) was used." | 3.75 | Guaifenesin enhances the analgesic potency of ibuprofen, nimesulide and celecoxib in mice. ( Dolezal, T; Krsiak, M; Sliva, J; Sykora, D; Vosmanska, M, 2009) |
| "Formation of reactive oxygen species and mitochondrial/lysosomal damages were significantly inhibited by both acetylsalicylic acid and celecoxib in hepatocytes of all pain- suffering animals." | 3.74 | Involvement of subcellular organelles in inflammatory pain-induced oxidative stress and apoptosis in the rat hepatocytes. ( Ahmadiani, A; Pourahmad, J; Rasekh, HR; Rezaei, M, 2008) |
| " This study was undertaken to apply the diffusion of innovations theory to the prescribing of celecoxib and to determine if prescriber and patient characteristics differed amongst early use of celecoxib for acute pain versus chronic musculoskeletal conditions." | 3.74 | Use of celecoxib immediately post marketing in Canada: acute or chronic pain? ( Kozyrskyj, AL; Racher, A; Raymond, C, 2007) |
| "The purpose of this study is to clarify involvement ratios between central and peripheral cyclooxygenase (COX)-2 in rat inflammatory pain models, by evaluating celecoxib and [6-chloro-2-(4-chlorobenzoyl)-1H-indol-3-yl]acetic acid (CIAA) on carrageenan-induced mechanical and thermal hyperalgesia." | 3.74 | Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA. ( Kita, Y; Murata, Y; Okumura, T; Sakakibara, A, 2008) |
| "Morphine and its congener opioids are the main therapy for severe pain in cancer." | 3.74 | COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. ( Farooqui, M; Griffin, RJ; Gupta, K; Li, Y; Poonawala, T; Rogers, T; Song, CW, 2007) |
| "The analgesic effects of celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, on formalin-induced pain are still controversial." | 3.73 | Analgesic effects of intrathecally administered celecoxib, a cyclooxygenase-2 inhibitor, in the tail flick test and the formalin test in rats. ( Nishiyama, T, 2006) |
| "The peripheral antinociceptive effect of the selective COX-2 inhibitor celecoxib in the formalin-induced inflammatory pain was compared with that of resveratrol (COX-1 inhibitor) and diclofenac (non-selective COX inhibitor)." | 3.71 | Comparison of the antinociceptive effect of celecoxib, diclofenac and resveratrol in the formalin test. ( Alonso-López, R; Asomoza-Espinosa, R; Castañeda-Hernández, G; Granados-Soto, V; Ortiz, MI; Torres-López, JE, 2002) |
| " No difference in adverse events was observed between the two groups." | 2.87 | Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial. ( Wang, J, 2018) |
| " Four additional DILI cases were identified after LY3031207 dosing had been stopped." | 2.87 | Dose-dependent acute liver injury with hypersensitivity features in humans due to a novel microsomal prostaglandin E synthase 1 inhibitor. ( Campanale, K; Hall, DG; Henck, J; Hu, L; Jin, Y; Kam, J; Landschulz, W; McNearney, TA; Nakano, M; Phipps, K; Regev, A; Smith, C; Uetrecht, J; Yang, XY, 2018) |
| "We compared the pharmacokinetic (PK) profiles of co-crystal of tramadol-celecoxib (CTC) vs." | 2.87 | Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a four-way randomized open-label phase I clinical trial. ( Encina, G; Escriche, M; Gascón, N; Lahjou, M; Plata-Salamán, C; Sans, A; Sicard, E; Soler, L; Sust, M; Vaqué, A; Videla, S, 2018) |
| " Adverse drug reactions may be renal, gastrointestinal, hematological, or immunologic." | 2.82 | Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years. ( Gorenflo, M; Saur, P; van den Anker, JN; van Dyk, M; Welzel, T; Ziesenitz, VC, 2022) |
| " Low solubility and bioavailability issues related with celecoxib lead to the development and advancement in the discovery and research of some possible formulation administered either orally, topically or via transdermal route." | 2.66 | A journey of celecoxib from pain to cancer. ( Purohit, P; Saxena, P; Sharma, PK, 2020) |
| "Patients with osteoarthritis are often affected by a number of cardiovascular comorbidities, including hypertension, which is present in about 40% of cases." | 2.58 | Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain. ( Angeli, F; Reboldi, G; Signorotti, S; Trapasso, M; Verdecchia, P, 2018) |
| " Furthermore, the panel agreed there is substantial evidence to indicate that cost savings can be achieved by using celecoxib in patients at moderate to high risk of gastrointestinal adverse events, even in countries with moderate healthcare expenditures." | 2.49 | A review of the efficacy, safety, and cost-effectiveness of COX-2 inhibitors for Africa and the Middle East region. ( Al Sayed, B; Bargaoui, N; Djebbar, M; Djennane, M; Donald, R; El Deeb, K; Joudeh, RA; Nabhan, A; Schug, SA; Zeidan, AZ, 2013) |
| "Celecoxib is an orally administered coxib." | 2.46 | [Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review]. ( Mateos, JL, 2010) |
| " However, clinical data suggest that chronic use of celecoxib, may impair normal skeletal function leading to decreased bone mineral density in older male patients." | 2.44 | Celecoxib, NSAIDs and the skeleton. ( Lysz, T; O'Connor, JP, 2008) |
| " Following oral administration, the less lipophilic celecoxib has a lower bioavailability (20-40%) than the other two coxibs (74-100%)." | 2.44 | Clinical use and pharmacological properties of selective COX-2 inhibitors. ( Klotz, U; Shi, S, 2008) |
| " However, NSAIDs cause significant adverse upper gastrointestinal effects, including increased mortality from serious ulcer complications." | 2.41 | Selective inhibitors of COX-2--are they safe for the stomach? ( Giercksky, KE; Haglund, U; Rask-Madsen, J, 2000) |
| " During repeated dosage with the specific COX-2 inhibitors, the 24 hour urinary excretion of sodium is only inhibited for the first day of treatment while the excretion of sodium is still decreased over the first 3 hours after the individual doses." | 2.41 | Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol). ( Day, RO; Graham, GG; Graham, RI, 2002) |
| "Pain is the major symptom that leads patients to consult their physicians for the treatment of arthritis; therefore, effective pain control is an important goal in the management of this disorder." | 2.40 | Pain management in osteoarthritis: the role of COX-2 inhibitors. ( Lane, NE, 1997) |
| "Tramadol and celecoxib were recently released as a new drug combination to alleviate intense, sudden pain when other pain medications had failed." | 1.91 | Green micelle and complex inclusion enhance synchronous spectrofluorimetric quantification of a novel analgesic combination: Tramadol and celecoxib in tablet dosage form and spiked human plasma. ( Bahgat, EA; Eissa, MS; Hashem, H; Kamel, EB; Saleh, H, 2023) |
| "Pain is a global, complex health problem that includes physical, emotional, and social components." | 1.72 | Quantitative Spectrophotometric Analysis of Celecoxib and Tramadol in Their Multimodal Analgesia Combination Tablets. ( Abdel-Fattah, A; Abdel-Monem, AH; Abdelazim, AH; Almrasy, AA; Ramzy, S; Shahin, M, 2022) |
| "Mechanical allodynia, heat hyperalgesia, biased weight-bearing, and hindpaw thickness were assessed 0." | 1.62 | Antinociception produced by nonsteroidal anti-inflammatory drugs in female vs male rats. ( Britch, SC; Craft, RM; Hewitt, KA, 2021) |
| "Metformin was administered orally every day to rats with OA." | 1.62 | Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy-Lysosomal Pathway. ( Cho, KH; Cho, ML; Choi, JW; Jung, K; Kim, SJ; Kwon, JY; Lee, AR; Lee, DH; Lee, SH; Lee, SY; Min, HK; Na, HS; Park, SH; Woo, JS, 2021) |
| "Pain is a prevalent PD's non-motor symptom with a higher prevalence of analgesic drugs prescription for patients." | 1.56 | Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease. ( Bortolanza, M; Crivelaro do Nascimento, G; Del Bel, EA; Ferrari, DP; Ferreira-Junior, NC; Guimaraes, FS, 2020) |
| "Kartogenin (KGN) is a small drug-like molecule that induces chondrogenesis in mesenchymal stem cells (MSCs)." | 1.48 | Kartogenin inhibits pain behavior, chondrocyte inflammation, and attenuates osteoarthritis progression in mice through induction of IL-10. ( Cho, KH; Cho, ML; Choi, J; Jung, K; Kim, SJ; Kwon, JY; Lee, CY; Lee, SH; Na, HS; Park, SH; Shin, DY, 2018) |
| "Diclofenac treatment produced dose-related reversal of CRANE at 0." | 1.42 | Complete Freund's adjuvant-induced reduction of exploratory activity in a novel environment as an objective nociceptive endpoint for sub-acute inflammatory pain model in rats. ( Bannon, AW; Joshi, SK; Zhu, CZ, 2015) |
| " Dose-dependent cardiac toxicity limits long-term use of celecoxib." | 1.42 | The cancer pain related factors affected by celecoxib together with cetuximab in head and neck squamous cell carcinoma. ( Chen, Z; Hu, R; Huang, Y; Jiang, H; Jiang, J; Xu, H; Yan, J; Yang, Y; Zhang, Y, 2015) |
| "Pain is the most common complaint in the medical field and the identification of novel compounds that can effectively treat painful states without causing side effects remains a major challenge in biomedical research." | 1.40 | Antinociceptive effect of 3-(4-fluorophenyl)-5-trifluoromethyl-1H-1-tosylpyrazole. A Celecoxib structural analog in models of pathological pain. ( Bonacorso, HG; Correa, MS; Ferreira, J; Oliveira, SM; Otuki, MF; Paim, GR; Prudente, AS; Silva, CR; Wentz, AP, 2014) |
| "Celecoxib was chosen as a comparator, given its clinical efficacy for alleviating pain in osteoarthritis patients and its peripheral and central pharmacological action." | 1.39 | Pharmacological modulation of brain activity in a preclinical model of osteoarthritis. ( Baker, SJ; Bannon, A; Beaver, J; Cassar, S; Chandran, P; Day, M; Fox, GB; Hart, M; Honore, P; Hooker, BA; Joshi, SK; Kamath, RV; Medema, JK; Mikusa, JP; Rajagovindan, R; Tovcimak, A; Upadhyay, J; Wald, MJ, 2013) |
| "Benzothiazole amides were identified as TRPV1 antagonists from high throughput screening using recombinant human TRPV1 receptor and structure-activity relationships were explored to pinpoint key pharmacophore interactions." | 1.38 | Potent and orally efficacious benzothiazole amides as TRPV1 antagonists. ( Besidski, Y; Brown, W; Bylund, J; Dabrowski, M; Dautrey, S; Griffin, AM; Harter, M; Horoszok, L; Hu, Y; Johnson, D; Johnstone, S; Jones, P; Kers, I; Kolmodin, K; Labarre, M; Labrecque, D; Laird, J; Leclerc, S; Lundström, T; Martino, J; Maudet, M; Munro, A; Nylöf, M; Penwell, A; Rotticci, D; Slaitas, A; Sundgren-Andersson, A; Svensson, M; Terp, G; Villanueva, H; Walpole, C; Zemribo, R, 2012) |
| "The treatment with celecoxib did not modify substantially the histological alterations and the number of active osteoclasts after activation of orthodontic appliance." | 1.38 | Celecoxib treatment does not alter recruitment and activation of osteoclasts in the initial phase of experimental tooth movement. ( Carvalho-Filho, EP; Ervolino, E; Iyomasa, MM; Rocha, MJ; Stabile, AC; Stuani, MB, 2012) |
| " Chronic administration of a cyclooxygenase (COX)-2 inhibitor is effective to bone cancer-related pain." | 1.37 | Microsomal prostaglandin E synthase-1 enhances bone cancer growth and bone cancer-related pain behaviors in mice. ( Akira, S; DeClerck, YA; Hayashi, I; Hosono, K; Isono, M; Majima, M; Okamoto, H; Sakagami, H; Suzuki, T; Uematsu, S, 2011) |
| "Inflammation was induced in one hind paw of rats by intraplantar injection of carrageenan (250 μg)." | 1.36 | Is the sulphonamide radical in the celecoxib molecule essential for its analgesic activity? ( Bakhle, YS; de Francischi, JN; dos Reis, WG; Ferreira-Alves, DL; Gassani, BC; Paiva-Lima, P; Rezende, RM, 2010) |
| "Celecoxib is a selective inhibitor of cyclooxygenase-2 (COX-2) and blocks prostaglandin (PG) biosynthesis associated with inflammatory conditions." | 1.35 | The analgesic actions of centrally administered celecoxib are mediated by endogenous opioids. ( Bakhle, YS; de Francischi, JN; Dos Reis, WG; Duarte, ID; Lima, PP; Rezende, RM, 2009) |
| "Kaposiform hemangioendothelioma is a rare vascular tumor of childhood that is locally aggressive but has little metastatic potential and by itself is not known to be lethal." | 1.35 | Kaposiform hemangioendothelioma in multiple spinal levels without skin changes. ( Bradeen, HA; Kalof, AN; Lisle, JW, 2009) |
| "Nimesulide had a potency lower than those of celecoxib, and DFU." | 1.34 | Additive interaction of intraperitoneal dexmedetomidine and topical nimesulide, celecoxib, and DFU for antinociception. ( Bagcivan, I; Cetin, A; Gulturk, S; Gursoy, S; Karadas, B; Kaya, T; Parlak, A, 2007) |
| "Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor used in the treatment of osteoarthritis and rheumatoid arthritis with fewer gastrointestinal toxicities compared to traditional non-steroidal anti-inflammatory drugs." | 1.34 | Celecoxib inhibits Na+ currents in rat dorsal root ganglion neurons. ( Kim, HI; Kim, TH; Lee, CS; Park, M; Park, SY; Shin, YK; Song, JH, 2007) |
| "Eosinophilic fasciitis (EF) is a rare connective tissue disorder characterized by symmetrical sclerodermatous skin changes primarily affecting the extremities and histologically, by thickening of the fascia with chronic inflammatory infiltrate containing eosinophils." | 1.34 | Eosinophilic fasciitis in a 57-year-old Japanese-American woman. ( Ambrocio, DU; Uramoto, K, 2007) |
| "Swelling and mechanical and thermal hyperalgesia were assessed before and for 28 days after the onset of arthritis." | 1.34 | Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade. ( Anand, P; Essex, D; Feldmann, M; Inglis, JJ; Notley, CA; Williams, R; Wilson, AW, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (3.28) | 18.2507 |
| 2000's | 79 (43.17) | 29.6817 |
| 2010's | 69 (37.70) | 24.3611 |
| 2020's | 29 (15.85) | 2.80 |
| Authors | Studies |
|---|---|
| Black, WC | 1 |
| Brideau, C | 1 |
| Chan, CC | 1 |
| Charleson, S | 1 |
| Cromlish, W | 1 |
| Gordon, R | 1 |
| Grimm, EL | 1 |
| Hughes, G | 1 |
| Leger, S | 1 |
| Li, CS | 1 |
| Riendeau, D | 1 |
| Thérien, M | 1 |
| Wang, Z | 2 |
| Xu, LJ | 1 |
| Prasit, P | 1 |
| Biava, M | 2 |
| Porretta, GC | 2 |
| Poce, G | 2 |
| Supino, S | 1 |
| Manetti, F | 1 |
| Forli, S | 1 |
| Botta, M | 1 |
| Sautebin, L | 2 |
| Rossi, A | 2 |
| Pergola, C | 1 |
| Ghelardini, C | 2 |
| Norcini, M | 1 |
| Makovec, F | 1 |
| Giordani, A | 2 |
| Anzellotti, P | 1 |
| Cirilli, R | 1 |
| Ferretti, R | 1 |
| Gallinella, B | 1 |
| La Torre, F | 1 |
| Anzini, M | 1 |
| Patrignani, P | 2 |
| da Silva, YK | 1 |
| Augusto, CV | 1 |
| de Castro Barbosa, ML | 1 |
| de Albuquerque Melo, GM | 1 |
| de Queiroz, AC | 1 |
| de Lima Matos Freire Dias, T | 1 |
| Júnior, WB | 1 |
| Barreiro, EJ | 1 |
| Lima, LM | 1 |
| Alexandre-Moreira, MS | 1 |
| Besidski, Y | 1 |
| Brown, W | 1 |
| Bylund, J | 1 |
| Dabrowski, M | 1 |
| Dautrey, S | 1 |
| Harter, M | 1 |
| Horoszok, L | 1 |
| Hu, Y | 1 |
| Johnson, D | 1 |
| Johnstone, S | 1 |
| Jones, P | 1 |
| Leclerc, S | 1 |
| Kolmodin, K | 1 |
| Kers, I | 1 |
| Labarre, M | 1 |
| Labrecque, D | 1 |
| Laird, J | 1 |
| Lundström, T | 1 |
| Martino, J | 1 |
| Maudet, M | 1 |
| Munro, A | 1 |
| Nylöf, M | 1 |
| Penwell, A | 1 |
| Rotticci, D | 1 |
| Slaitas, A | 1 |
| Sundgren-Andersson, A | 1 |
| Svensson, M | 1 |
| Terp, G | 1 |
| Villanueva, H | 1 |
| Walpole, C | 1 |
| Zemribo, R | 1 |
| Griffin, AM | 1 |
| Battilocchio, C | 1 |
| Alfonso, S | 1 |
| Consalvi, S | 1 |
| Pace, S | 1 |
| Di Cesare Mannelli, L | 1 |
| Schenone, S | 1 |
| Di Francesco, L | 1 |
| Gaba, M | 1 |
| Singh, S | 1 |
| Mohan, C | 1 |
| Singh, A | 1 |
| Kaur, M | 2 |
| Sharma, S | 1 |
| Bhatti, R | 2 |
| Singh, P | 2 |
| Haider, S | 1 |
| Alam, MS | 1 |
| Hamid, H | 1 |
| Shafi, S | 1 |
| Dhulap, A | 1 |
| Hussain, F | 1 |
| Alam, P | 1 |
| Umar, S | 1 |
| Pasha, MA | 1 |
| Bano, S | 1 |
| Nazreen, S | 1 |
| Ali, Y | 1 |
| Kharbanda, C | 1 |
| Parsons, WH | 1 |
| Calvo, RR | 1 |
| Cheung, W | 1 |
| Lee, YK | 1 |
| Patel, S | 1 |
| Liu, J | 3 |
| Youngman, MA | 1 |
| Dax, SL | 1 |
| Stone, D | 1 |
| Qin, N | 1 |
| Hutchinson, T | 1 |
| Lubin, ML | 1 |
| Zhang, SP | 1 |
| Finley, M | 1 |
| Liu, Y | 1 |
| Brandt, MR | 1 |
| Flores, CM | 1 |
| Player, MR | 1 |
| Hwang, SH | 1 |
| Wagner, K | 1 |
| Xu, J | 1 |
| Yang, J | 1 |
| Li, X | 2 |
| Cao, Z | 1 |
| Morisseau, C | 1 |
| Lee, KS | 1 |
| Hammock, BD | 1 |
| Guan, LP | 1 |
| Xia, YN | 1 |
| Jin, QH | 1 |
| Liu, BY | 1 |
| Wang, SH | 1 |
| Healy, MP | 1 |
| Allan, AC | 1 |
| Bailey, K | 1 |
| Billinton, A | 1 |
| Chessell, IP | 1 |
| Clayton, NM | 1 |
| Giblin, GMP | 1 |
| Kay, MA | 1 |
| Khaznadar, T | 1 |
| Michel, AD | 1 |
| Naylor, A | 1 |
| Price, H | 1 |
| Spalding, DJ | 1 |
| Stevens, DA | 1 |
| Swarbrick, ME | 1 |
| Wilson, AW | 2 |
| Kaur, S | 1 |
| Kumari, P | 1 |
| Kaur, B | 1 |
| Singh, G | 2 |
| Bhatti, M | 1 |
| Al-Ostoot, FH | 1 |
| Grisha, S | 1 |
| Mohammed, YHE | 1 |
| Vivek, HK | 1 |
| Ara Khanum, S | 1 |
| Tian, Y | 1 |
| Li, S | 2 |
| Yang, P | 1 |
| Su, X | 1 |
| Lv, X | 1 |
| Dong, K | 1 |
| Yang, T | 1 |
| Duan, M | 1 |
| Hu, G | 1 |
| Yue, H | 1 |
| Sun, Y | 3 |
| Zhang, H | 1 |
| Du, Z | 1 |
| Miao, Z | 1 |
| Tong, M | 1 |
| Hou, Y | 1 |
| Gao, Z | 1 |
| Zhao, Y | 1 |
| de Campos, GC | 1 |
| de Almeida Macedo, E | 1 |
| Kummer, AM | 1 |
| Papaleo Rosim, M | 1 |
| Millan Fachi, M | 1 |
| Auletta, LL | 1 |
| Reyes-Sosa, R | 1 |
| Lugo-Radillo, A | 1 |
| Cruz-Santiago, L | 1 |
| Garcia-Cruz, CR | 1 |
| Mendoza-Cano, O | 1 |
| Zhang, XY | 1 |
| Barakat, A | 1 |
| Diaz-delCastillo, M | 1 |
| Vollert, J | 1 |
| Sena, ES | 1 |
| Heegaard, AM | 1 |
| Rice, ASC | 1 |
| Soliman, N | 1 |
| Abdelazim, AH | 1 |
| Ramzy, S | 1 |
| Abdel-Monem, AH | 1 |
| Almrasy, AA | 1 |
| Abdel-Fattah, A | 1 |
| Shahin, M | 1 |
| Ziesenitz, VC | 1 |
| Welzel, T | 1 |
| van Dyk, M | 1 |
| Saur, P | 1 |
| Gorenflo, M | 1 |
| van den Anker, JN | 1 |
| Kumar, M | 1 |
| Dogra, R | 1 |
| Mandal, UK | 1 |
| Sun, Q | 1 |
| Zhang, Y | 2 |
| Ding, Y | 1 |
| Xie, W | 1 |
| Li, H | 1 |
| Li, Y | 2 |
| Cai, M | 1 |
| Wang, C | 1 |
| Zhu, JC | 1 |
| Zheng, ZW | 1 |
| Xiong, YZ | 1 |
| Ma, XF | 1 |
| Gong, YC | 1 |
| He, YL | 1 |
| Tellegen, AR | 2 |
| Rudnik-Jansen, I | 2 |
| Utomo, L | 2 |
| Versteeg, S | 2 |
| Beukers, M | 2 |
| Maarschalkerweerd, R | 2 |
| van Zuilen, D | 2 |
| van Klaveren, NJ | 2 |
| Houben, K | 2 |
| Teske, E | 2 |
| van Weeren, PR | 2 |
| Karssemakers-Degen, N | 2 |
| Mihov, G | 2 |
| Thies, J | 2 |
| Eijkelkamp, N | 2 |
| Creemers, LB | 2 |
| Meij, BP | 2 |
| Tryfonidou, MA | 2 |
| Veronese, N | 2 |
| Ecarnot, F | 2 |
| Cheleschi, S | 2 |
| Fioravanti, A | 2 |
| Maggi, S | 2 |
| Xiang, XN | 2 |
| Zhu, SY | 2 |
| Song, KP | 2 |
| Wang, XY | 2 |
| Liu, HZ | 2 |
| Yang, WJ | 2 |
| Wang, H | 2 |
| Zhang, C | 2 |
| Yang, L | 2 |
| He, C | 2 |
| Zhou, Y | 2 |
| Liu, X | 1 |
| Ding, C | 1 |
| Xiang, B | 1 |
| Yan, L | 1 |
| Bahgat, EA | 1 |
| Hashem, H | 1 |
| Saleh, H | 1 |
| Kamel, EB | 1 |
| Eissa, MS | 1 |
| Zhou, J | 1 |
| Zeng, F | 1 |
| Cheng, S | 1 |
| Dong, X | 1 |
| Jiang, N | 1 |
| Zhang, X | 1 |
| Tang, C | 1 |
| He, W | 1 |
| Chen, Y | 1 |
| Sun, N | 1 |
| Hu, S | 1 |
| Sun, R | 1 |
| Wintermark, M | 1 |
| Yang, W | 2 |
| Liang, F | 1 |
| Li, Z | 2 |
| Murdoch, I | 1 |
| Carver, AL | 1 |
| Sultan, P | 1 |
| O'Carroll, JE | 1 |
| Blake, L | 1 |
| Carvalho, B | 1 |
| Onwochei, DN | 1 |
| Desai, N | 1 |
| Nogrady, B | 1 |
| Crivelaro do Nascimento, G | 1 |
| Ferrari, DP | 1 |
| Guimaraes, FS | 1 |
| Del Bel, EA | 1 |
| Bortolanza, M | 1 |
| Ferreira-Junior, NC | 1 |
| Saxena, P | 1 |
| Sharma, PK | 1 |
| Purohit, P | 1 |
| Park, MS | 1 |
| Kang, CN | 1 |
| Lee, WS | 1 |
| Kim, HJ | 1 |
| Lee, S | 1 |
| Kim, JH | 1 |
| Shin, SJ | 1 |
| Moon, SH | 1 |
| Oliveira, DH | 1 |
| Sousa, FSS | 1 |
| Birmann, PT | 1 |
| Alves, D | 1 |
| Jacob, RG | 1 |
| Savegnago, L | 1 |
| Liu, L | 1 |
| Karagoz, H | 1 |
| Herneisey, M | 1 |
| Zor, F | 1 |
| Komatsu, T | 1 |
| Loftus, S | 1 |
| Janjic, BM | 1 |
| Gorantla, VS | 1 |
| Janjic, JM | 1 |
| El-Hazek, RMM | 1 |
| El-Sabbagh, WA | 1 |
| El-Hazek, RM | 1 |
| El-Gazzar, MG | 1 |
| Huang, H | 1 |
| Luo, M | 1 |
| Liang, H | 1 |
| Pan, J | 1 |
| Zeng, L | 1 |
| Liang, G | 1 |
| Hou, S | 1 |
| Zhao, J | 1 |
| Craft, RM | 1 |
| Hewitt, KA | 1 |
| Britch, SC | 1 |
| Na, HS | 2 |
| Kwon, JY | 2 |
| Lee, SY | 1 |
| Lee, SH | 2 |
| Lee, AR | 1 |
| Woo, JS | 1 |
| Jung, K | 2 |
| Cho, KH | 2 |
| Choi, JW | 1 |
| Lee, DH | 1 |
| Min, HK | 1 |
| Park, SH | 3 |
| Kim, SJ | 2 |
| Cho, ML | 3 |
| Gowayed, MA | 1 |
| Abdel-Bary, A | 1 |
| El-Tahan, RA | 1 |
| Piszczatoski, CR | 1 |
| Smith, SM | 1 |
| Zhao, YQ | 1 |
| Wang, HY | 1 |
| Yin, JB | 1 |
| Wang, Y | 2 |
| Liang, JC | 1 |
| Guo, XJ | 1 |
| Tang, K | 1 |
| Wang, YT | 1 |
| Wang, J | 1 |
| Breivik, H | 1 |
| Jin, Y | 2 |
| Regev, A | 1 |
| Kam, J | 1 |
| Phipps, K | 1 |
| Smith, C | 2 |
| Henck, J | 1 |
| Campanale, K | 1 |
| Hu, L | 1 |
| Hall, DG | 1 |
| Yang, XY | 1 |
| Nakano, M | 1 |
| McNearney, TA | 2 |
| Uetrecht, J | 1 |
| Landschulz, W | 1 |
| Yang, S | 1 |
| Wang, X | 1 |
| Jiang, H | 2 |
| Lu, H | 1 |
| Videla, S | 1 |
| Lahjou, M | 1 |
| Vaqué, A | 1 |
| Sust, M | 1 |
| Escriche, M | 1 |
| Soler, L | 1 |
| Sans, A | 1 |
| Sicard, E | 1 |
| Gascón, N | 2 |
| Encina, G | 2 |
| Plata-Salamán, C | 2 |
| Tintara, H | 1 |
| Voradithi, P | 1 |
| Choobun, T | 1 |
| Bruyère, O | 1 |
| Ghasemi, A | 1 |
| Danesh, B | 1 |
| Yazdani-Charati, J | 1 |
| Hosseinimehr, SJ | 1 |
| Choi, J | 1 |
| Lee, CY | 1 |
| Shin, DY | 1 |
| Monteith, D | 1 |
| Brown, R | 1 |
| Camporeale, A | 1 |
| Deeg, MA | 1 |
| Raddad, E | 1 |
| Xiao, N | 1 |
| de la Peña, A | 1 |
| Kivitz, AJ | 1 |
| Schnitzer, TJ | 3 |
| Angeli, F | 1 |
| Trapasso, M | 1 |
| Signorotti, S | 1 |
| Verdecchia, P | 1 |
| Reboldi, G | 1 |
| Suwa, Y | 1 |
| Watanabe, J | 1 |
| Ota, M | 1 |
| Suzuki, S | 1 |
| Suwa, H | 1 |
| Watanabe, K | 1 |
| Saito, S | 1 |
| Nagamine, K | 1 |
| Momiyama, M | 1 |
| Ishibe, A | 1 |
| Saigusa, Y | 1 |
| Yamanaka, T | 1 |
| Endo, I | 1 |
| Sakurai, Y | 1 |
| Fujita, M | 1 |
| Kawasaki, S | 1 |
| Sanaki, T | 1 |
| Yoshioka, T | 1 |
| Higashino, K | 1 |
| Tofukuji, S | 1 |
| Yoneda, S | 1 |
| Takahashi, T | 1 |
| Koda, K | 1 |
| Asaki, T | 1 |
| Hasegawa, M | 1 |
| Morioka, Y | 1 |
| Karateev, AE | 1 |
| Pogozheva, EY | 1 |
| Filatova, EA | 1 |
| Amirjanova, VN | 1 |
| Lila, AM | 1 |
| Antipova, OV | 1 |
| Babaeva, AR | 1 |
| Volkorezova, AV | 1 |
| Davydova, AF | 1 |
| Davtyan, VG | 1 |
| Zonova, EV | 1 |
| Ivanova, ON | 1 |
| Kalinina, NN | 1 |
| Kiseleva, NI | 1 |
| Knyazeva, LA | 1 |
| Kulikov, AI | 1 |
| Nesmeyanova, OB | 1 |
| Mazurov, VI | 1 |
| Masneva, LV | 1 |
| Menshikova, LV | 1 |
| Obuhova, IV | 1 |
| Otteva, EN | 1 |
| Salnikova, TS | 1 |
| Shсhendrygin, IN | 1 |
| Yakupova, SP | 1 |
| Shamsi Meymandi, M | 1 |
| Sepehri, G | 1 |
| Izadi, G | 1 |
| Zamiri, Z | 1 |
| Almansa, C | 1 |
| Merlos, M | 1 |
| Miguel Vela, J | 1 |
| Morte, A | 1 |
| Smith, K | 1 |
| Reed, GW | 1 |
| Nissen, SE | 1 |
| Essex, MN | 1 |
| Zhang, RY | 1 |
| Berger, MF | 1 |
| Upadhyay, S | 1 |
| Park, PW | 1 |
| Conaghan, PG | 1 |
| Dickson, J | 1 |
| Bolten, W | 1 |
| Cevc, G | 1 |
| Rother, M | 1 |
| Sifferlin, A | 1 |
| Stepanovic-Petrovic, RM | 1 |
| Micov, AM | 1 |
| Tomic, MA | 1 |
| Kovacevic, JM | 1 |
| Boškovic, BD | 1 |
| Scheinfeld, N | 1 |
| Trudeau, J | 1 |
| Van Inwegen, R | 1 |
| Eaton, T | 1 |
| Bhat, G | 1 |
| Paillard, F | 1 |
| Ng, D | 1 |
| Tan, K | 1 |
| Katz, NP | 1 |
| Rodriguez-Merchan, EC | 1 |
| de la Corte-Rodriguez, H | 1 |
| Jimenez-Yuste, V | 1 |
| Oliveira, SM | 1 |
| Silva, CR | 1 |
| Wentz, AP | 1 |
| Paim, GR | 1 |
| Correa, MS | 1 |
| Bonacorso, HG | 1 |
| Prudente, AS | 1 |
| Otuki, MF | 1 |
| Ferreira, J | 1 |
| Rabinow, B | 1 |
| Werling, J | 1 |
| Bendele, A | 1 |
| Gass, J | 1 |
| Bogseth, R | 1 |
| Balla, K | 1 |
| Valaitis, P | 1 |
| Hutchcraft, A | 1 |
| Graham, S | 1 |
| Kvasnovsky, CL | 1 |
| Aujla, U | 1 |
| Bjarnason, I | 1 |
| Bannuru, RR | 1 |
| Schmid, CH | 1 |
| Kent, DM | 1 |
| Vaysbrot, EE | 1 |
| Wong, JB | 1 |
| McAlindon, TE | 1 |
| Zhu, CZ | 1 |
| Bannon, AW | 1 |
| Joshi, SK | 2 |
| Yang, Y | 1 |
| Yan, J | 1 |
| Huang, Y | 1 |
| Xu, H | 1 |
| Hu, R | 1 |
| Jiang, J | 1 |
| Chen, Z | 1 |
| Hou, CF | 1 |
| Wei, S | 1 |
| Chen, ZH | 1 |
| Li, XH | 1 |
| Wang, ST | 1 |
| Guo, J | 1 |
| Holt, RJ | 1 |
| Fort, JG | 2 |
| Grahn, AY | 1 |
| Kent, JD | 1 |
| Bello, AE | 2 |
| Katz, JN | 1 |
| Smith, SR | 1 |
| Collins, JE | 1 |
| Solomon, DH | 1 |
| Jordan, JM | 1 |
| Hunter, DJ | 1 |
| Suter, LG | 1 |
| Yelin, E | 1 |
| Paltiel, AD | 1 |
| Losina, E | 1 |
| Hassan, A | 1 |
| Wahba, A | 1 |
| Haggag, H | 1 |
| Gould, SA | 1 |
| Doods, H | 1 |
| Lamla, T | 1 |
| Pekcec, A | 1 |
| Arendt-Nielsen, L | 1 |
| Harris, S | 1 |
| Whiteside, GT | 1 |
| Hummel, M | 1 |
| Knappenberger, T | 1 |
| O'Keefe, S | 1 |
| Kapil, R | 1 |
| Kyle, D | 1 |
| Gordo, AC | 1 |
| Walker, C | 1 |
| Armada, B | 1 |
| Zhou, D | 1 |
| Rezaei, M | 1 |
| Rasekh, HR | 1 |
| Ahmadiani, A | 1 |
| Pourahmad, J | 1 |
| Hochberg, MC | 1 |
| Clegg, DO | 2 |
| O'Connor, JP | 1 |
| Lysz, T | 1 |
| Rezende, RM | 3 |
| Dos Reis, WG | 3 |
| Duarte, ID | 1 |
| Lima, PP | 1 |
| Bakhle, YS | 3 |
| de Francischi, JN | 2 |
| Inoue, N | 1 |
| Ito, S | 1 |
| Tajima, K | 1 |
| Nogawa, M | 1 |
| Takahashi, Y | 1 |
| Sasagawa, T | 1 |
| Nakamura, A | 1 |
| Kyoi, T | 1 |
| Lisle, JW | 1 |
| Bradeen, HA | 1 |
| Kalof, AN | 1 |
| Paulsen, G | 1 |
| Egner, IM | 1 |
| Drange, M | 1 |
| Langberg, H | 1 |
| Benestad, HB | 1 |
| Fjeld, JG | 1 |
| Hallén, J | 1 |
| Raastad, T | 1 |
| Boyce-Rustay, JM | 1 |
| Zhong, C | 1 |
| Kohnken, R | 1 |
| Baker, SJ | 2 |
| Simler, GH | 1 |
| Wensink, EJ | 1 |
| Decker, MW | 1 |
| Honore, P | 2 |
| Shibazaki, T | 1 |
| Yozgatian, JH | 1 |
| Zeredo, JL | 1 |
| Gonzales, C | 1 |
| Hotokezaka, H | 1 |
| Koga, Y | 1 |
| Yoshida, N | 1 |
| Sliva, J | 1 |
| Dolezal, T | 1 |
| Sykora, D | 1 |
| Vosmanska, M | 1 |
| Krsiak, M | 2 |
| Ross, E | 1 |
| DeLemos, BP | 1 |
| Xiang, J | 1 |
| Benson, C | 1 |
| Gana, TJ | 1 |
| Pascual, ML | 1 |
| Rosanna, R | 1 |
| Fleming, B | 1 |
| Mateos, JL | 1 |
| Luo, R | 1 |
| Liu, G | 1 |
| Liu, W | 1 |
| Pei, F | 1 |
| Zhou, Z | 1 |
| Li, J | 1 |
| Shen, B | 1 |
| Kang, P | 1 |
| Xie, Q | 1 |
| Ma, X | 1 |
| Gassani, BC | 1 |
| Paiva-Lima, P | 2 |
| Ferreira-Alves, DL | 1 |
| Kang, M | 1 |
| Jung, I | 1 |
| Hur, J | 1 |
| Kim, SH | 1 |
| Lee, JH | 1 |
| Kang, JY | 1 |
| Jung, KC | 1 |
| Kim, KS | 1 |
| Yoo, MC | 1 |
| Park, DS | 1 |
| Lee, JD | 1 |
| Cho, YB | 1 |
| Ferland, CE | 1 |
| Laverty, S | 1 |
| Beaudry, F | 1 |
| Vachon, P | 1 |
| Isono, M | 1 |
| Suzuki, T | 1 |
| Hosono, K | 1 |
| Hayashi, I | 1 |
| Sakagami, H | 1 |
| Uematsu, S | 1 |
| Akira, S | 1 |
| DeClerck, YA | 1 |
| Okamoto, H | 1 |
| Majima, M | 1 |
| Schachtel, BP | 1 |
| McCabe, D | 1 |
| Berger, M | 1 |
| Zhang, R | 1 |
| Sanner, KM | 1 |
| Savino, L | 1 |
| Rizouk, J | 1 |
| Schachtel, EP | 1 |
| Janovsky, M | 1 |
| Camêlo, VM | 1 |
| Faraco, A | 1 |
| Francischi, JN | 1 |
| Zeidan, AZ | 1 |
| Al Sayed, B | 1 |
| Bargaoui, N | 1 |
| Djebbar, M | 1 |
| Djennane, M | 1 |
| Donald, R | 1 |
| El Deeb, K | 1 |
| Joudeh, RA | 1 |
| Nabhan, A | 1 |
| Schug, SA | 1 |
| Upadhyay, J | 1 |
| Rajagovindan, R | 1 |
| Hart, M | 1 |
| Chandran, P | 1 |
| Hooker, BA | 1 |
| Cassar, S | 1 |
| Mikusa, JP | 1 |
| Tovcimak, A | 1 |
| Wald, MJ | 1 |
| Bannon, A | 1 |
| Medema, JK | 1 |
| Beaver, J | 1 |
| Kamath, RV | 1 |
| Fox, GB | 1 |
| Day, M | 1 |
| Dong, J | 1 |
| Jiang, D | 1 |
| Wu, G | 1 |
| Miao, L | 1 |
| Huang, L | 1 |
| Moore, A | 1 |
| Makinson, G | 1 |
| Li, C | 1 |
| de Rienzo-Madero, B | 1 |
| Coffeen, U | 1 |
| Simón-Arceo, K | 1 |
| Mercado, F | 1 |
| Jaimes, O | 1 |
| Magis-Weinberg, L | 1 |
| Contreras, B | 1 |
| Pellicer, F | 1 |
| Moon, SJ | 1 |
| Park, JS | 1 |
| Jeong, JH | 1 |
| Yang, EJ | 1 |
| Park, MK | 1 |
| Kim, EK | 1 |
| Kim, HY | 1 |
| Min, JK | 1 |
| Carvalho-Filho, EP | 1 |
| Stabile, AC | 1 |
| Ervolino, E | 1 |
| Stuani, MB | 1 |
| Iyomasa, MM | 1 |
| Rocha, MJ | 1 |
| García-Rodríguez, RM | 1 |
| Hinojosa, M | 1 |
| Camacho-Garrido, E | 1 |
| Berges Gimeno, P | 1 |
| Martín García, C | 1 |
| Finucane, TE | 1 |
| Hayes, EC | 1 |
| Rock, JA | 1 |
| Rowbotham, DJ | 1 |
| Salo, DF | 1 |
| Lavery, R | 1 |
| Varma, V | 1 |
| Goldberg, J | 1 |
| Shapiro, T | 1 |
| Kenwood, A | 1 |
| Burdan, F | 1 |
| Korobowicz, A | 1 |
| Collantes-Estevez, E | 1 |
| Fernandez-Perez, C | 1 |
| Bianchi, M | 1 |
| Broggini, M | 1 |
| Burian, M | 1 |
| Geisslinger, G | 2 |
| Emkey, R | 1 |
| Rosenthal, N | 1 |
| Wu, SC | 1 |
| Jordan, D | 1 |
| Kamin, M | 1 |
| Li, SQ | 1 |
| Li, WB | 1 |
| Leeb, BF | 1 |
| Bucsi, L | 1 |
| Keszthelyi, B | 1 |
| Böhmova, J | 1 |
| Valesova, M | 1 |
| Hawel, R | 1 |
| Mayrhofer, F | 1 |
| Singer, F | 1 |
| Aglas, F | 1 |
| Bröll, H | 1 |
| Hsueh, SF | 1 |
| Lu, CY | 1 |
| Chao, CS | 1 |
| Tan, PH | 1 |
| Huang, YW | 1 |
| Hsieh, SW | 1 |
| Hsiao, HT | 1 |
| Chung, NC | 1 |
| Lin, SH | 1 |
| Huang, PL | 1 |
| Lyu, PC | 1 |
| Yang, LC | 1 |
| White, WB | 1 |
| Jayr, C | 2 |
| Tran, F | 1 |
| Boggie, DT | 1 |
| Delattre, ML | 1 |
| Schaefer, MG | 1 |
| Morreale, AP | 1 |
| Plowman, BK | 1 |
| Zanchet, EM | 1 |
| Longo, I | 1 |
| Cury, Y | 1 |
| Lyseng-Williamson, KA | 1 |
| Curran, MP | 1 |
| Pomonis, JD | 1 |
| Boulet, JM | 1 |
| Gottshall, SL | 1 |
| Phillips, S | 1 |
| Sellers, R | 1 |
| Bunton, T | 1 |
| Walker, K | 2 |
| Noguchi, M | 1 |
| Kimoto, A | 1 |
| Kobayashi, S | 1 |
| Yoshino, T | 1 |
| Miyata, K | 1 |
| Sasamata, M | 1 |
| Weaver, AL | 1 |
| Polis, AB | 1 |
| Petruschke, RA | 1 |
| Geba, GP | 1 |
| Fleischmann, R | 1 |
| Sheldon, E | 1 |
| Maldonado-Cocco, J | 1 |
| Dutta, D | 1 |
| Yu, S | 1 |
| Sloan, VS | 1 |
| Whitehouse, MW | 1 |
| Nishiyama, T | 1 |
| Goldstein, JL | 1 |
| Levy, RA | 1 |
| Hanrahan, PS | 1 |
| Andrade-Ortega, L | 1 |
| Wallemark, C | 1 |
| Agrawal, NM | 1 |
| Eisen, GM | 1 |
| Stenson, WF | 1 |
| Triadafilopoulos, G | 1 |
| Reda, DJ | 1 |
| Harris, CL | 1 |
| Klein, MA | 1 |
| O'Dell, JR | 1 |
| Hooper, MM | 1 |
| Bradley, JD | 1 |
| Bingham, CO | 1 |
| Weisman, MH | 1 |
| Jackson, CG | 1 |
| Lane, NE | 2 |
| Cush, JJ | 1 |
| Moreland, LW | 1 |
| Schumacher, HR | 1 |
| Oddis, CV | 1 |
| Wolfe, F | 1 |
| Molitor, JA | 1 |
| Yocum, DE | 1 |
| Furst, DE | 1 |
| Sawitzke, AD | 1 |
| Shi, H | 1 |
| Brandt, KD | 1 |
| Moskowitz, RW | 1 |
| Williams, HJ | 1 |
| Zochling, J | 1 |
| Bohl-Bühler, MH | 1 |
| Baraliakos, X | 1 |
| Feldtkeller, E | 1 |
| Braun, J | 1 |
| Traynor, K | 1 |
| Lin, EH | 1 |
| Curley, SA | 1 |
| Crane, CC | 1 |
| Feig, B | 1 |
| Skibber, J | 1 |
| Delcos, M | 1 |
| Vadhan, SR | 1 |
| Morris, J | 1 |
| Ayers, GD | 1 |
| Ross, A | 1 |
| Brown, T | 1 |
| Rodriguez-Bigas, MA | 1 |
| Janjan, N | 1 |
| Karadas, B | 1 |
| Kaya, T | 1 |
| Gulturk, S | 1 |
| Parlak, A | 1 |
| Gursoy, S | 1 |
| Cetin, A | 1 |
| Bagcivan, I | 1 |
| Hilário, MO | 1 |
| Terreri, MT | 1 |
| Len, CA | 1 |
| Donley, BG | 1 |
| Moore, T | 1 |
| Sferra, J | 1 |
| Gozdanovic, J | 1 |
| Smith, R | 1 |
| Kozyrskyj, AL | 1 |
| Raymond, C | 1 |
| Racher, A | 1 |
| Park, SY | 1 |
| Kim, TH | 1 |
| Kim, HI | 1 |
| Shin, YK | 1 |
| Lee, CS | 1 |
| Park, M | 1 |
| Song, JH | 1 |
| Ambrocio, DU | 1 |
| Uramoto, K | 1 |
| Song, YW | 1 |
| Lee, EY | 1 |
| Koh, EM | 1 |
| Cha, HS | 1 |
| Yoo, B | 1 |
| Lee, CK | 1 |
| Baek, HJ | 1 |
| Kim, HA | 1 |
| Suh, Y | 1 |
| Kang, SW | 1 |
| Lee, YJ | 1 |
| Jung, HG | 1 |
| Okumura, T | 1 |
| Sakakibara, A | 1 |
| Murata, Y | 1 |
| Kita, Y | 1 |
| Farooqui, M | 1 |
| Rogers, T | 1 |
| Poonawala, T | 1 |
| Griffin, RJ | 1 |
| Song, CW | 1 |
| Gupta, K | 1 |
| Frampton, JE | 1 |
| Keating, GM | 1 |
| Shi, S | 1 |
| Klotz, U | 1 |
| Inglis, JJ | 1 |
| Notley, CA | 1 |
| Essex, D | 1 |
| Feldmann, M | 1 |
| Anand, P | 1 |
| Williams, R | 1 |
| Lee, IO | 1 |
| Seo, Y | 1 |
| Brink, S | 1 |
| Karch, AM | 1 |
| Karch, FE | 1 |
| Rodgers, E | 1 |
| Tindall, E | 1 |
| Hinz, B | 1 |
| Brune, K | 1 |
| Clemett, D | 1 |
| Goa, KL | 1 |
| Lantz, MS | 1 |
| Giambanco, V | 1 |
| Giercksky, KE | 1 |
| Haglund, U | 1 |
| Rask-Madsen, J | 1 |
| Cannon, GW | 1 |
| Breedveld, FC | 1 |
| Tive, L | 1 |
| Stichtenoth, DO | 1 |
| Frölich, JC | 1 |
| Maddrey, WC | 1 |
| Maurath, CJ | 1 |
| Verburg, KM | 1 |
| Geis, GS | 1 |
| Pfister, AK | 1 |
| Crisalli, RJ | 1 |
| Carter, WH | 1 |
| Nasonova, VA | 1 |
| Comarow, A | 1 |
| Adler, J | 1 |
| Nakamura, H | 1 |
| Kessenich, CR | 1 |
| Tegeder, I | 1 |
| Niederberger, E | 1 |
| Vetter, G | 1 |
| Bräutigam, L | 1 |
| Zuurmond, WW | 1 |
| Granados-Soto, V | 2 |
| Alonso-López, R | 2 |
| Asomoza-Espinosa, R | 2 |
| Rufino, MO | 1 |
| Gomes-Lopes, LD | 1 |
| Ferreira, SH | 1 |
| Yamamoto, T | 1 |
| Nozaki-Taguchi, N | 1 |
| Medhurst, SJ | 1 |
| Bowes, M | 1 |
| Kidd, BL | 1 |
| Glatt, M | 1 |
| Muller, M | 1 |
| Hattenberger, M | 1 |
| Vaxelaire, J | 1 |
| O'Reilly, T | 1 |
| Wotherspoon, G | 1 |
| Winter, J | 1 |
| Green, J | 1 |
| Urban, L | 1 |
| Graham, GG | 1 |
| Graham, RI | 1 |
| Day, RO | 1 |
| Torres-López, JE | 1 |
| Ortiz, MI | 1 |
| Castañeda-Hernández, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Randomized, Double-Blind, Placebo and Active-Controlled Trial of LY2951742 in Patients With Mild to Moderate Osteoarthritis Pain of the Knee[NCT02192190] | Phase 2 | 268 participants (Actual) | Interventional | 2014-07-31 | Terminated (stopped due to Interim assessment: Lack of efficacy) | ||
| A Randomised, Double-blind, Placebo Controlled Study of Topical FLEXISEQ® for the Treatment of Osteoarthritis of the Knee in Patients Contraindicated for or With Clinical Intolerance to NSAIDs[NCT02594176] | 600 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | |||
| Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Study of Safety and Efficacy of Two Dosages of Epicutaneously Applied Diractin® (Ketoprofen in Transfersome® Gel) for the Treatment of Osteoarthritis of the Knee[NCT00716547] | Phase 3 | 1,399 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Pilot, Open Non-controled Trial to Assess the Feasibility of Implementing Objective Parameters as Primary Endpoints in a Clinical Trial With Patients Affected by Knee Osteoarthritis[NCT03421054] | 8 participants (Actual) | Interventional | 2018-03-19 | Completed | |||
| Double Blind, Placebo Controlled Trial to Evaluate the Effects of a Nutraceutical Containing High-Molecular-Weight Hyaluronic Acid (HA) and Acetyl-11-Keto-Beta-Boswellic Acid (AKBA) in Patients Affected by Knee Osteoarthritis[NCT03612986] | 72 participants (Actual) | Interventional | 2018-08-22 | Completed | |||
| Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Center Study Evaluating the Efficacy of PN400 (VIMOVO) Twice Daily (Bid) and Celecoxib Once Daily (qd) in Patients With Osteoarthritis of the Knee[NCT00665431] | Phase 3 | 610 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Center Study Evaluating the Efficacy of PN400 (VIMOVO) Twice Daily (Bid) and Celecoxib Once Daily (qd) in Patients With Osteoarthritis of the Knee[NCT00664560] | Phase 3 | 614 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Tramadol Versus Celecoxib for Reducing Pain Associated With Outpatient Hysteroscopy: A Randomized Double Blind Placebo-Controlled Trial[NCT02071303] | Phase 2 | 210 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Tramadol Versus Celecoxib in Reducing Pain Associated With IUD Insertion: A Double Blind Placebo Controlled Trial[NCT02827487] | Phase 4 | 210 participants (Anticipated) | Interventional | 2016-07-01 | Recruiting | ||
| Tramadol Versus Celecoxib for Reducing Pain During Operative Office Hysteroscopy: A Double Blind Placebo Controlled Trial.[NCT02736071] | Phase 3 | 210 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| Tramadol Versus Celecoxib for Reducing Pain During Office Hysteroscopy in Post Menopausal Women: A Double Blind Randomized Controlled Trial[NCT02736019] | Phase 3 | 210 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| A Study of the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) and Three Times Daily Ibuprofen vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee[NCT00630929] | Phase 4 | 388 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)[NCT00032890] | Phase 3 | 1,588 participants | Interventional | 2000-04-30 | Completed | ||
| Study of the Effect of Chondroitin Sulphate on Synovial Inflammation in Patients With Osteoarthritis of the Knee[NCT00604539] | Phase 3 | 70 participants (Anticipated) | Interventional | 2008-02-29 | Completed | ||
| Investigation of Oral Glucosamine Effects on Synovial Fluid Viscosity and Viscoelasticity in Osteoarthritis Patients[NCT01074476] | 20 participants (Anticipated) | Interventional | 2015-06-30 | Active, not recruiting | |||
| IRB-HSR# 13957: IV Lidocaine for Patients Undergoing Primary Breast Cancer Surgery: Effects on Postoperative Recovery and Cancer Recurrence[NCT01204242] | Phase 2 | 78 participants (Actual) | Interventional | 2009-08-01 | Completed | ||
| Pain Modulation in RA - Influence of Adalimumab. A Randomized, Placebo-controlled Study Using Functional Magnetic Resonance Imaging (PARADE)[NCT01197144] | 70 participants (Actual) | Interventional | 2010-10-31 | Completed | |||
| The Effects of Bariatric Surgery Weight Loss on Knee Pain in Patients With Osteoarthritis of the Knee[NCT00752765] | 30 participants (Anticipated) | Observational | 2008-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The 24-question WOMAC Osteoarthritis Index assesses osteoarthritis (OA) symptoms using pain (5 questions), stiffness (2 questions) and physical function (17 questions) subscales. The WOMAC pain subscale was calculated for each participant at each time point for analysis as the mean score (range 0-100 millimeter [mm] VAS; 0=very good and 100=very poor) of all 5 questions related to pain. Bayesian posterior adjusted mean was calculated using a Bayesian Normal Dynamic Linear Model (NDLM) dose response model with baseline and pooled investigator site included as baseline covariates. (NCT02192190)
Timeframe: Baseline, 8 Weeks
| Intervention | mm (Least Squares Mean) |
|---|---|
| Placebo | -19.2 |
| Celecoxib | -31.3 |
| LY2951742 5 mg + Placebo | -16.4 |
| LY2951742 50 mg + Placebo | -24.2 |
| LY2951742 120 mg + Placebo | -21.8 |
| LY2951742 300 mg + Placebo | -17.7 |
The 24-question WOMAC Osteoarthritis Index assesses osteoarthritis symptoms using pain (5 questions), stiffness (2 questions) and physical function (17 questions) subscales. The WOMAC Osteoarthritis Index version 3.1 was administered according to the study schedule. The WOMAC physical function subscale was calculated for each participant at each time point for analysis as the mean score (range 0-100 mm VAS; 0=very good and 100=very poor) of all 17 questions related to physical function. Least Square Mean (LSM) was calculated using a mixed-effects model repeated measures (MMRM) approach with treatment, visit and the interaction of treatment and visit were fitted as fixed effects in the model and baseline and pooled investigator site as baseline covariates. (NCT02192190)
Timeframe: Baseline, 8 Weeks
| Intervention | mm (Least Squares Mean) |
|---|---|
| Placebo | -16.5 |
| Celecoxib | -30.6 |
| LY2951742 5 mg + Placebo | -15.4 |
| LY2951742 50 mg + Placebo | -23.5 |
| LY2951742 120 mg + Placebo | -19.5 |
| LY2951742 300 mg + Placebo | -18.4 |
The 24-question WOMAC Osteoarthritis Index assesses osteoarthritis symptoms using pain (5 questions), stiffness (2 questions) and physical function (17 questions) subscales. The WOMAC stiffness subscale will be calculated for each participant at each time point for analysis as the mean score (range 0-100 mm VAS; 0=very good and 100=very poor) of 2 questions related to stiffness. LSM mean was calculated using a mixed-effects model repeated measures (MMRM) approach with treatment, visit and the interaction of treatment and visit were fitted as fixed effects in the model and baseline and pooled investigator site as baseline covariates. LSM mean was calculated using a mixed-effects model repeated measures (MMRM) approach with treatment, visit and the interaction of treatment and visit were fitted as fixed effects in the model and baseline and pooled investigator site as baseline covariates. (NCT02192190)
Timeframe: Baseline, 8 Weeks
| Intervention | mm (Least Squares Mean) |
|---|---|
| Placebo | -18.5 |
| Celecoxib | -31.4 |
| LY2951742 5 mg + Placebo | -15.1 |
| LY2951742 50 mg + Placebo | -23.7 |
| LY2951742 120 mg + Placebo | -21.3 |
| LY2951742 300 mg + Placebo | -17.3 |
The 24-question WOMAC Osteoarthritis Index assesses osteoarthritis symptoms using pain (5 questions), stiffness (2 questions) and physical function (17 questions) subscales.The WOMAC total score was calculated for each participant at each time point for analysis as the mean score (range 0-100 mm VAS; 0=very good and 100=very poor) of 24 questions. LSM mean was calculated using a mixed-effects model repeated measures (MMRM) approach with treatment, visit and the interaction of treatment and visit were fitted as fixed effects in the model and baseline and pooled investigator site as baseline covariates. LSM mean was calculated using a mixed-effects model repeated measures (MMRM) approach with treatment, visit and the interaction of treatment and visit were fitted as fixed effects in the model and baseline and pooled investigator site as baseline covariates. (NCT02192190)
Timeframe: Baseline, 8 Weeks
| Intervention | mm (Least Squares Mean) |
|---|---|
| Placebo | -17.0 |
| Celecoxib | -31.1 |
| LY2951742 5 mg + Placebo | -15.6 |
| LY2951742 50 mg + Placebo | -23.7 |
| LY2951742 120 mg + Placebo | -20.0 |
| LY2951742 300 mg + Placebo | -18.4 |
"The PGA is a patient-rated instrument that measures their assessment of overall OA symptoms. It is based on the participant's response to the question Considering all the ways your osteoarthritis affects you, how are you doing today? using a 100 mm VAS (0=very good and 100=very poor). LSM mean was calculated using a mixed-effects model repeated measures (MMRM) approach with treatment, visit and the interaction of treatment and visit were fitted as fixed effects in the model and baseline and pooled investigator site as baseline covariates." (NCT02192190)
Timeframe: Baseline, 8 Weeks
| Intervention | mm (Least Squares Mean) |
|---|---|
| Placebo | -22.5 |
| Celecoxib | -36.7 |
| LY2951742 5 mg + Placebo | -18.5 |
| LY2951742 50 mg + Placebo | -19.4 |
| LY2951742 120 mg + Placebo | -21.2 |
| LY2951742 300 mg + Placebo | -20.4 |
The responders according to OMERACT-OARSI criteria: participants with at least 50 % improvement in pain or in function scores, along with absolute improvement of 20 mm, were considered responders. Alternatively, participants were considered responders if they showed at least 20% improvement and absolute improvement of 10 mm in at least two of the following scores: pain, function and Patients Global Assessment (PGA) scores. (NCT02192190)
Timeframe: 8 Weeks
| Intervention | participants (Number) |
|---|---|
| Placebo | 21 |
| Celecoxib | 14 |
| LY2951742 5 mg + Placebo | 7 |
| LY2951742 50 mg + Placebo | 15 |
| LY2951742 120 mg + Placebo | 10 |
| LY2951742 300 mg + Placebo | 10 |
Tablet pill count (NCT00665431)
Timeframe: 12 weeks
| Intervention | Tablets per subject (Mean) |
|---|---|
| (PN 400 (VIMOVO) Twice Daily) | 13.4 |
| (Celebrex 200 mg Once Daily) | 20.9 |
| (Placebo Twice Daily) | 27.3 |
PGA questionnaire. The patient global assessment (PGA) question asks about how the subject is doing considering his/her arthritis and is measured by a visual analog scale (VAS); 0 mm (very poor) 100 mm (excellent). The outcome measures a change from baseline PGA in mm. (NCT00665431)
Timeframe: 12 Weeks
| Intervention | mm (Mean) |
|---|---|
| (PN 400 (VIMOVO) Twice Daily) | 27.7 |
| (Celebrex 200 mg Once Daily) | 26.4 |
| (Placebo Twice Daily) | 22.4 |
PGA questionnaire. The patient global assessment (PGA) question asks about how the subject is doing considering his/her arthritis and is measured by a visual analog scale (VAS); 0 mm (very poor) 100 mm (excellent). The outcome measures a change from baseline PGA in mm. (NCT00665431)
Timeframe: Week 6
| Intervention | mm (Mean) |
|---|---|
| (PN 400 (VIMOVO) Twice Daily) | 25.9 |
| (Celebrex 200 mg Once Daily) | 24.4 |
| (Placebo Twice Daily) | 22.3 |
"WOMAC function questionnaire (VAS). The 17 questions about function all use visual analog scale (VAS) of 100 mm; 0 mm being no pain and 100 mm being extreme pain. The outcome measures a change in WOMAC pain from baseline (in mm).~The Western Ontario and McMaster Universities (WOMAC) is a self-administered, patient-reported health status questionnaire that is designed to capture elements of pain, stiffness and physical disability in patients with OA of the knee and/or hip joints. The index consists of 24 questions (5 questions about pain, 2 on stiffness and 17 about physical function)." (NCT00665431)
Timeframe: 12 Weeks
| Intervention | mm (Mean) |
|---|---|
| (PN 400 (VIMOVO) Twice Daily) | -38.7 |
| (Celebrex 200 mg Once Daily) | -37.7 |
| (Placebo Twice Daily) | -30.9 |
"WOMAC function questionnaire (VAS). The 17 questions about function all use visual analog scale (VAS) of 100 mm; 0 mm being no pain and 100 mm being extreme pain. The outcome measures a change in WOMAC pain from baseline (in mm).~The Western Ontario and McMaster Universities (WOMAC) is a self-administered, patient-reported health status questionnaire that is designed to capture elements of pain, stiffness and physical disability in patients with OA of the knee and/or hip joints. The index consists of 24 questions (5 questions about pain, 2 on stiffness and 17 about physical function)." (NCT00665431)
Timeframe: Week 6
| Intervention | mm (Mean) |
|---|---|
| (PN 400 (VIMOVO) Twice Daily) | -38.5 |
| (Celebrex 200 mg Once Daily) | -34.6 |
| (Placebo Twice Daily) | -29.0 |
"Western Ontario and McMaster Universities (WOMAC) pain questionnaire has 5 questions on pain all use visual analog scale (VAS) of 100 mm, with 0 mm being no pain and 100 mm being extreme pain. The outcome measures a change in WOMAC pain at 12 weeks from baseline (in mm). WOMAC is a self-administered, patient-reported health status questionnaire designed to capture elements of pain, stiffness and physical disability in patients with OA of the knee and/or hip joints. It consists of 24 questions (5 questions about pain, 2 on stiffness and 17 about physical function)." (NCT00665431)
Timeframe: Baseline and 12 Weeks
| Intervention | mm (Mean) |
|---|---|
| (PN 400 (VIMOVO) Twice Daily) | -44.1 |
| (Celebrex 200 mg Once Daily) | -43.6 |
| (Placebo Twice Daily) | -37.3 |
"Western Ontario and McMaster Universities (WOMAC) pain questionnaire has 5 questions on pain all use visual analog scale (VAS) of 100 mm, with 0 mm being no pain and 100 mm being extreme pain. The outcome measures a change in WOMAC pain at 6 weeks from baseline (in mm). WOMAC is a self-administered, patient-reported health status questionnaire designed to capture elements of pain, stiffness and physical disability in patients with OA of the knee and/or hip joints. It consists of 24 questions (5 questions about pain, 2 on stiffness and 17 about physical function)." (NCT00665431)
Timeframe: Week 6
| Intervention | mm (Mean) |
|---|---|
| (PN 400 (VIMOVO) Twice Daily) | -44.3 |
| (Celebrex 200 mg Once Daily) | -39.6 |
| (Placebo Twice Daily) | -33.9 |
For APS-POQ score is the change from Baseline scores calculated for each subject through Day 7. Scale 0 through 70, where 0=no pain interference and 70=complete interference. (NCT00665431)
Timeframe: Baseline and Day 7
| Intervention | Units on a scale (Mean) |
|---|---|
| (PN 400 (VIMOVO) Twice Daily) | -18.8 |
| (Celebrex 200 mg Once Daily) | -16.6 |
| (Placebo Twice Daily) | -11.6 |
Change from Baseline in the Modified Severity of Dyspepsia Assessment (mSODA) average daily pain intensity converted total score at Week 12. The mSODA instruments consists of 6 questions about abdominal discomfort during the past 24 hours, with a converted score of 2 through 47. Lower score equals less pain. (NCT00665431)
Timeframe: 12 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| (PN 400 (VIMOVO) Twice Daily) | -4.5 |
| (Celebrex 200 mg Once Daily) | -3.3 |
| (Placebo Twice Daily) | -3.5 |
Number of participants reporting pre-specified non-steroidal antiinflammatory drug-associated (NSAID) upper gastrointestinal (UGI) symptoms. Pre-specified NSAID-associated UGI symptoms include adverse events such as dyspepsia, abdominal pain or discomfort, nausea, vomiting. (NCT00665431)
Timeframe: daily during 12 weeks
| Intervention | participants (Number) |
|---|---|
| (PN 400 (VIMOVO) Twice Daily) | 46 |
| (Celebrex 200 mg Once Daily) | 53 |
| (Placebo Twice Daily) | 25 |
During 12 weeks, daily heartburn question with ratings none, mild, moderate, or severe. Percent of days with Heartburn resolution (heartburn is none). (NCT00665431)
Timeframe: 12 weeks
| Intervention | percent days (Mean) |
|---|---|
| (PN 400 (VIMOVO) Twice Daily) | 78.4 |
| (Celebrex 200 mg Once Daily) | 72.1 |
| (Placebo Twice Daily) | 71.1 |
The number of subjects who discontinued from the study due to any pre-specified non-steroidal antiinflammatory drug (NSAID)-associated upper gastrointestinal (UGI) adverse event (as classified by MedDRA). Pre-specified NSAID-associated UGI symptoms include adverse events such as dyspepsia, abdominal pain or discomfort, nausea, vomiting. (NCT00665431)
Timeframe: daily during 12 weeks
| Intervention | participants (Number) |
|---|---|
| (PN 400 (VIMOVO) Twice Daily) | 2 |
| (Celebrex 200 mg Once Daily) | 9 |
| (Placebo Twice Daily) | 3 |
Mean change from Baseline scores calculated for each subject through Day 7. Scale 0 through 70, where 0=no pain interference and 70=complete interference. (NCT00664560)
Timeframe: Baseline and Day 7
| Intervention | Units on a scale (Mean) |
|---|---|
| (PN 400 (VIMOVO) Twice Daily) | -17.8 |
| (Celebrex 200 mg Once Daily) | -17.7 |
| (Placebo Twice Daily) | -12.8 |
Tablet pill count (NCT00664560)
Timeframe: 12 weeks
| Intervention | Tablets per subject (Mean) |
|---|---|
| (PN 400 (VIMOVO) Twice Daily) | 9.3 |
| (Celebrex 200 mg Once Daily) | 13.9 |
| (Placebo Twice Daily) | 15.4 |
PGA questionnaire. The patient global assessment (PGA) question asks about how the subject is doing considering his/her arthritis and is measured by a visual analog scale (VAS); 0 mm (very poor) 100 mm (excellent). The outcome measures a change from baseline PGA in mm. (NCT00664560)
Timeframe: 12 weeks
| Intervention | mm (Mean) |
|---|---|
| (PN 400 (VIMOVO) Twice Daily) | 21.5 |
| (Celebrex 200 mg Once Daily) | 22.4 |
| (Placebo Twice Daily) | 12.4 |
PGA questionnaire. The patient global assessment (PGA) question asks about how the subject is doing considering his/her arthritis and is measured by a visual analog scale (VAS); 0 mm (very poor) 100 mm (excellent). The outcome measures a change from baseline PGA in mm. (NCT00664560)
Timeframe: Week 6
| Intervention | mm (Mean) |
|---|---|
| (PN 400 (VIMOVO) Twice Daily) | 22.6 |
| (Celebrex 200 mg Once Daily) | 20.7 |
| (Placebo Twice Daily) | 14.7 |
"WOMAC function questionnaire (VAS). The 17 questions about function all use visual analog scale (VAS) of 100 mm; 0 mm being no pain and 100 mm being extreme pain. The outcome measures a change in WOMAC pain from baseline (in mm).~The Western Ontario and McMaster Universities (WOMAC) is a self-administered, patient-reported health status questionnaire that is designed to capture elements of pain, stiffness and physical disability in patients with OA of the knee and/or hip joints. The index consists of 24 questions (5 questions about pain, 2 on stiffness and 17 about physical function)." (NCT00664560)
Timeframe: 12 weeks
| Intervention | mm (Mean) |
|---|---|
| (PN 400 (VIMOVO) Twice Daily) | -37.5 |
| (Celebrex 200 mg Once Daily) | -36.0 |
| (Placebo Twice Daily) | -28.9 |
"WOMAC function questionnaire (VAS). The 17 questions about function all use visual analog scale (VAS) of 100 mm; 0 mm being no pain and 100 mm being extreme pain. The outcome measures a change in WOMAC pain from baseline (in mm).~The Western Ontario and McMaster Universities (WOMAC) is a self-administered, patient-reported health status questionnaire that is designed to capture elements of pain, stiffness and physical disability in patients with OA of the knee and/or hip joints. The index consists of 24 questions (5 questions about pain, 2 on stiffness and 17 about physical function)." (NCT00664560)
Timeframe: Week 6
| Intervention | mm (Mean) |
|---|---|
| (PN 400 (VIMOVO) Twice Daily) | -35.3 |
| (Celebrex 200 mg Once Daily) | -33.9 |
| (Placebo Twice Daily) | -27.3 |
"Western Ontario and McMaster Universities (WOMAC) pain questionnaire has 5 questions on pain all use visual analog scale (VAS) of 100 mm, with 0 mm being no pain and 100 mm being extreme pain. The outcome measures a change in WOMAC pain at 12 weeks from baseline (in mm). WOMAC is a self-administered, patient-reported health status questionnaire designed to capture elements of pain, stiffness and physical disability in patients with OA of the knee and/or hip joints. It consists of 24 questions (5 questions about pain, 2 on stiffness and 17 about physical function)." (NCT00664560)
Timeframe: Baseline and 12 weeks
| Intervention | mm (Mean) |
|---|---|
| (PN 400 (VIMOVO) Twice Daily) | -43.4 |
| (Celebrex 200 mg Once Daily) | -41.1 |
| (Placebo Twice Daily) | -34.0 |
"Western Ontario and McMaster Universities (WOMAC) pain questionnaire has 5 questions on pain all use visual analog scale (VAS) of 100 mm, with 0 mm being no pain and 100 mm being extreme pain. The outcome measures a change in WOMAC pain at 6 weeks from baseline (in mm). WOMAC is a self-administered, patient-reported health status questionnaire designed to capture elements of pain, stiffness and physical disability in patients with OA of the knee and/or hip joints. It consists of 24 questions (5 questions about pain, 2 on stiffness and 17 about physical function)." (NCT00664560)
Timeframe: Week 6
| Intervention | mm (Mean) |
|---|---|
| (PN 400 (VIMOVO) Twice Daily) | -40.9 |
| (Celebrex 200 mg Once Daily) | -39.4 |
| (Placebo Twice Daily) | -30.7 |
Change from Baseline in the Modified Severity of Dyspepsia Assessment (mSODA) average daily pain intensity converted total score at Week 12. The mSODA instruments consists of 6 questions about abdominal discomfort during the past 24 hours, with a converted score of 2 through 47. Lower score equals less pain. (NCT00664560)
Timeframe: Baseline to 12 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| (PN 400 (VIMOVO) Twice Daily) | -3.5 |
| (Celebrex 200 mg Once Daily) | -4.8 |
| (Placebo Twice Daily) | -4.0 |
Number of participants reporting pre-specified non-steroidal antiinflammatory drug-associated (NSAID) upper gastrointestinal (UGI) symptoms. Pre-specified NSAID-associated UGI symptoms include adverse events such as dyspepsia, abdominal pain or discomfort, nausea, vomiting. (NCT00664560)
Timeframe: daily during 12 weeks
| Intervention | participants (Number) |
|---|---|
| (PN 400 (VIMOVO) Twice Daily) | 41 |
| (Celebrex 200 mg Once Daily) | 41 |
| (Placebo Twice Daily) | 24 |
During 12 weeks, daily heartburn question with ratings none, mild, moderate, or severe. Percent of days with Heartburn resolution (heartburn is none). (NCT00664560)
Timeframe: 12 weeks
| Intervention | percent days (Mean) |
|---|---|
| (PN 400 (VIMOVO) Twice Daily) | 83.9 |
| (Celebrex 200 mg Once Daily) | 75.8 |
| (Placebo Twice Daily) | 68.5 |
The number of subjects who discontinued from the study due to any pre-specified non-steroidal antiinflammatory drug (NSAID)-associated upper gastrointestinal (UGI) adverse event (as classified by MedDRA). Pre-specified NSAID-associated UGI symptoms include adverse events such as dyspepsia, abdominal pain or discomfort, nausea, vomiting. (NCT00664560)
Timeframe: daily during 12 weeks
| Intervention | participants (Number) |
|---|---|
| (PN 400 (VIMOVO) Twice Daily) | 3 |
| (Celebrex 200 mg Once Daily) | 4 |
| (Placebo Twice Daily) | 3 |
42 reviews available for celecoxib and Ache
| Article | Year |
|---|---|
Benzimidazole: an emerging scaffold for analgesic and anti-inflammatory agents.
Topics: Analgesics; Anti-Inflammatory Agents; Benzimidazoles; Drug Discovery; Humans; Inflammation; Pain | 2014 |
Efficacy of ultramicronised diclofenac in patients with osteoarthritis - systematic review with network meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Humans; Network Meta-Analysis; Osteo | 2021 |
Systematic review and meta-analysis of studies in which burrowing behaviour was assessed in rodent models of disease-associated persistent pain.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Celecoxib; Disease M | 2022 |
Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years.
Topics: Adolescent; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; C | 2022 |
Possible synergic action of non-steroidal anti-inflammatory drugs and glucosamine sulfate for the treatment of knee osteoarthritis: a scoping review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Glucosamine; Humans; Observational Studies as To | 2022 |
Possible synergic action of non-steroidal anti-inflammatory drugs and glucosamine sulfate for the treatment of knee osteoarthritis: a scoping review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Glucosamine; Humans; Observational Studies as To | 2022 |
Possible synergic action of non-steroidal anti-inflammatory drugs and glucosamine sulfate for the treatment of knee osteoarthritis: a scoping review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Glucosamine; Humans; Observational Studies as To | 2022 |
Possible synergic action of non-steroidal anti-inflammatory drugs and glucosamine sulfate for the treatment of knee osteoarthritis: a scoping review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Glucosamine; Humans; Observational Studies as To | 2022 |
Comparison of different nonsteroidal anti-inflammatory drugs for cesarean section: a systematic review and network meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cesarean Section; Diclofenac; Female; Humans; In | 2023 |
A journey of celecoxib from pain to cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Humans; Inflam | 2020 |
Meta-analysis Comparing Celecoxib with Diclofenac Sodium in Patients with Knee Osteoarthritis.
Topics: Celecoxib; Diclofenac; Humans; Osteoarthritis, Knee; Pain; Treatment Outcome | 2021 |
Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain.
Topics: Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Celecoxib; Drug Combin | 2018 |
Co-crystal of tramadol-celecoxib: preclinical and clinical evaluation of a novel analgesic.
Topics: Analgesics, Opioid; Animals; Celecoxib; Crystallization; Cyclooxygenase 2 Inhibitors; Drug Combinati | 2019 |
Safety of celecoxib compared with placebo and non-selective NSAIDs: cumulative meta-analysis of 89 randomized controlled trials.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topi | 2013 |
Treatment of hidradenitis supprurativa associated pain with nonsteroidal anti-inflammatory drugs, acetaminophen, celecoxib, gabapentin, pegabalin, duloxetine, and venlafaxine.
Topics: Acetaminophen; Amines; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclohexaneca | 2013 |
Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cycl | 2015 |
Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.
Topics: Acetaminophen; Adrenal Cortex Hormones; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Ster | 2015 |
Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.
Topics: Acetaminophen; Adrenal Cortex Hormones; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Ster | 2015 |
Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.
Topics: Acetaminophen; Adrenal Cortex Hormones; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Ster | 2015 |
Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.
Topics: Acetaminophen; Adrenal Cortex Hormones; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Ster | 2015 |
Celecoxib, NSAIDs and the skeleton.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Bone and Bones; Bone Regeneration; Cele | 2008 |
Update on the management of pain in arthritis and the use of cyclooxygenase-2 inhibitors.
Topics: Arthritis; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Pain; Pyrazoles; Sulfonamides | 2009 |
[Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review].
Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Administration Routes; Evidence-Based Medicine | 2010 |
A review of the efficacy, safety, and cost-effectiveness of COX-2 inhibitors for Africa and the Middle East region.
Topics: Africa; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 2 Inhibitors; Humans; Middle East; Pain; Pa | 2013 |
Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials.
Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Gastrointestinal Tract; Humans; Pain; P | 2013 |
COX-2 inhibitors and their role in gynecology.
Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Administra | 2002 |
COX-2-selective inhibitors: clinical relevance in surgical and acute pain.
Topics: Acute Disease; Analgesics; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cycloo | 2002 |
[Coxibs: highly selective cyclooxygenase-2 inhibitors. Part I. Clinical efficacy].
Topics: Alzheimer Disease; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibito | 2003 |
[Clinical pharmacology of the selective COX-2 inhibitors].
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis | 2003 |
[Cyclooxygenases in the spinal cord and the relationship with pain].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyc | 2003 |
[Analgesic effects of cyclooxygenase 2 inhibitors].
Topics: Acute Disease; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Cycl | 2004 |
[Analgesic effects of cyclooxygenase 2 inhibitors].
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Female; H | 2004 |
Nonsteroidal anti-inflammatory drugs: cyclooxygenase 2 inhibitors.
Topics: Adolescent; Aspirin; Celecoxib; Child; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Interacti | 2006 |
Celecoxib: a review of its use in the management of arthritis and acute pain.
Topics: Acute Disease; Arthritis; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Pain; Pyrazoles; Sulfonami | 2007 |
Clinical use and pharmacological properties of selective COX-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibito | 2008 |
Pain management in osteoarthritis: the role of COX-2 inhibitors.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibit | 1997 |
Treating pain with COX-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Drug Costs; Drug Inte | 1999 |
Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox | 1999 |
Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.
Topics: Acute Disease; Animals; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Electron Transp | 2000 |
Selective inhibitors of COX-2--are they safe for the stomach?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox | 2000 |
Efficacy of cyclooxygenase-2-specific inhibitors.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxyge | 2001 |
Celecoxib clinical profile.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec | 2000 |
[Therapy with preferential and specific COX-2 inhibitors].
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 1; Cycl | 2001 |
The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Controlled Clinical Trial | 2000 |
[Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Colo | 2001 |
Cyclo-oxygenase 2 inhibitors: an important new drug classification.
Topics: Acute Disease; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Celecoxib; Chr | 2001 |
COX-2 inhibitors: no pain, no heart gain?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Cyclooxygenas | 2001 |
Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol).
Topics: Acetaminophen; Analgesia; Cardiovascular System; Celecoxib; Clinical Trials as Topic; Cyclooxygenase | 2002 |
40 trials available for celecoxib and Ache
| Article | Year |
|---|---|
Clinical comparison of platelet-rich plasma injection and daily celecoxib administration in the treatment of early knee osteoarthritis: A randomized clinical trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Humans; Hyaluronic Acid; Osteoarthritis, Knee; P | 2020 |
Sustained release of locally delivered celecoxib provides pain relief for osteoarthritis: a proof of concept in dog patients.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Delayed-Ac | 2023 |
Sustained release of locally delivered celecoxib provides pain relief for osteoarthritis: a proof of concept in dog patients.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Delayed-Ac | 2023 |
Sustained release of locally delivered celecoxib provides pain relief for osteoarthritis: a proof of concept in dog patients.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Delayed-Ac | 2023 |
Sustained release of locally delivered celecoxib provides pain relief for osteoarthritis: a proof of concept in dog patients.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Delayed-Ac | 2023 |
Pulsed electromagnetic fields for the management of knee osteoarthritis: multicentre, randomised, controlled, non-inferiority trial protocol.
Topics: Celecoxib; Electromagnetic Fields; Humans; Multicenter Studies as Topic; Osteoarthritis, Knee; Pain; | 2022 |
Pulsed electromagnetic fields for the management of knee osteoarthritis: multicentre, randomised, controlled, non-inferiority trial protocol.
Topics: Celecoxib; Electromagnetic Fields; Humans; Multicenter Studies as Topic; Osteoarthritis, Knee; Pain; | 2022 |
Pulsed electromagnetic fields for the management of knee osteoarthritis: multicentre, randomised, controlled, non-inferiority trial protocol.
Topics: Celecoxib; Electromagnetic Fields; Humans; Multicenter Studies as Topic; Osteoarthritis, Knee; Pain; | 2022 |
Pulsed electromagnetic fields for the management of knee osteoarthritis: multicentre, randomised, controlled, non-inferiority trial protocol.
Topics: Celecoxib; Electromagnetic Fields; Humans; Multicenter Studies as Topic; Osteoarthritis, Knee; Pain; | 2022 |
Positive Preemptive Analgesia Effectiveness of Pregabalin Combined with Celecoxib in Total Knee Arthroplasty: A Prospective Controlled Randomized Study.
Topics: Analgesia; Analgesics, Opioid; Arthroplasty, Replacement, Knee; C-Reactive Protein; Celecoxib; Doubl | 2023 |
Modulation effects of different treatments on periaqueductal gray resting state functional connectivity in knee osteoarthritis knee pain patients.
Topics: Acupuncture Therapy; Anti-Inflammatory Agents, Non-Steroidal; Capsules; Celecoxib; Humans; Magnetic | 2023 |
A comparative study of the efficacy of NAXOZOL compared to celecoxib in patients with osteoarthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Double-Blind Method; Es | 2020 |
Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial.
Topics: Adalimumab; Aged; Antirheumatic Agents; Celecoxib; Diclofenac; Female; Humans; Hyaluronic Acid; Ibup | 2018 |
Dose-dependent acute liver injury with hypersensitivity features in humans due to a novel microsomal prostaglandin E synthase 1 inhibitor.
Topics: Administration, Oral; Adult; Area Under Curve; Celecoxib; Chemical and Drug Induced Liver Injury; Cy | 2018 |
Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a four-way randomized open-label phase I clinical trial.
Topics: Adult; Analgesics, Opioid; Area Under Curve; Celecoxib; Cross-Over Studies; Crystallization; Cycloox | 2018 |
Effectiveness of celecoxib for pain relief and antipyresis in second trimester medical abortions with misoprostol: a randomized controlled trial.
Topics: Abortion, Therapeutic; Administration, Sublingual; Adult; Anti-Inflammatory Agents, Non-Steroidal; A | 2018 |
Pharmaceutical-grade chondroitin sulfate in the management of knee osteoarthritis.
Topics: Administration, Oral; Aged; Celecoxib; Chondroitin Sulfates; Double-Blind Method; Drug Administratio | 2018 |
Randomized Double-blind Placebo-controlled Trial of Celecoxib for the Prevention of Skin Toxicity in Patients Receiving Radiation Therapy for Breast Cancer.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Carcinoma, Ductal, Breast; Celecox | 2018 |
CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Calcitonin Gene-Related Peptide; Celecoxib; Dose-Res | 2018 |
Randomized phase II trial of the prophylactic use of celecoxib for the prevention of oxaliplatin-related peripheral vascular pain in Capeox (YCOG1205).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Celecoxib; Chemotherapy, Adjuvan | 2019 |
A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in Transfersome gel (IDEA-033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with osteoarthritis.
Topics: Administration, Oral; Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Age | 2013 |
A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in Transfersome gel (IDEA-033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with osteoarthritis.
Topics: Administration, Oral; Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Age | 2013 |
A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in Transfersome gel (IDEA-033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with osteoarthritis.
Topics: Administration, Oral; Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Age | 2013 |
A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in Transfersome gel (IDEA-033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with osteoarthritis.
Topics: Administration, Oral; Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Age | 2013 |
Assessment of pain and activity using an electronic pain diary and actigraphy device in a randomized, placebo-controlled crossover trial of celecoxib in osteoarthritis of the knee.
Topics: Actigraphy; Adult; Aged; Celecoxib; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Double-Blind Me | 2015 |
Assessment of pain and activity using an electronic pain diary and actigraphy device in a randomized, placebo-controlled crossover trial of celecoxib in osteoarthritis of the knee.
Topics: Actigraphy; Adult; Aged; Celecoxib; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Double-Blind Me | 2015 |
Assessment of pain and activity using an electronic pain diary and actigraphy device in a randomized, placebo-controlled crossover trial of celecoxib in osteoarthritis of the knee.
Topics: Actigraphy; Adult; Aged; Celecoxib; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Double-Blind Me | 2015 |
Assessment of pain and activity using an electronic pain diary and actigraphy device in a randomized, placebo-controlled crossover trial of celecoxib in osteoarthritis of the knee.
Topics: Actigraphy; Adult; Aged; Celecoxib; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Double-Blind Me | 2015 |
Efficacy of celecoxib in the treatment of joint pain caused by advanced haemophilic arthropathy in adult patients with haemophilia A.
Topics: Acetaminophen; Administration, Oral; Adult; Analgesics, Non-Narcotic; Celecoxib; Cyclooxygenase 2 In | 2014 |
Onset and durability of pain relief in knee osteoarthritis: Pooled results from two placebo trials of naproxen/esomeprazole combination and celecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method | 2015 |
Onset and durability of pain relief in knee osteoarthritis: Pooled results from two placebo trials of naproxen/esomeprazole combination and celecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method | 2015 |
Onset and durability of pain relief in knee osteoarthritis: Pooled results from two placebo trials of naproxen/esomeprazole combination and celecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method | 2015 |
Onset and durability of pain relief in knee osteoarthritis: Pooled results from two placebo trials of naproxen/esomeprazole combination and celecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method | 2015 |
Tramadol versus Celecoxib for reducing pain associated with outpatient hysteroscopy: a randomized double-blind placebo-controlled trial.
Topics: Adult; Analgesics, Opioid; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Huma | 2016 |
Tramadol versus Celecoxib for reducing pain associated with outpatient hysteroscopy: a randomized double-blind placebo-controlled trial.
Topics: Adult; Analgesics, Opioid; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Huma | 2016 |
Tramadol versus Celecoxib for reducing pain associated with outpatient hysteroscopy: a randomized double-blind placebo-controlled trial.
Topics: Adult; Analgesics, Opioid; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Huma | 2016 |
Tramadol versus Celecoxib for reducing pain associated with outpatient hysteroscopy: a randomized double-blind placebo-controlled trial.
Topics: Adult; Analgesics, Opioid; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Huma | 2016 |
Tramadol versus Celecoxib for reducing pain associated with outpatient hysteroscopy: a randomized double-blind placebo-controlled trial.
Topics: Adult; Analgesics, Opioid; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Huma | 2016 |
Tramadol versus Celecoxib for reducing pain associated with outpatient hysteroscopy: a randomized double-blind placebo-controlled trial.
Topics: Adult; Analgesics, Opioid; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Huma | 2016 |
Tramadol versus Celecoxib for reducing pain associated with outpatient hysteroscopy: a randomized double-blind placebo-controlled trial.
Topics: Adult; Analgesics, Opioid; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Huma | 2016 |
Tramadol versus Celecoxib for reducing pain associated with outpatient hysteroscopy: a randomized double-blind placebo-controlled trial.
Topics: Adult; Analgesics, Opioid; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Huma | 2016 |
Tramadol versus Celecoxib for reducing pain associated with outpatient hysteroscopy: a randomized double-blind placebo-controlled trial.
Topics: Adult; Analgesics, Opioid; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Huma | 2016 |
Tramadol versus Celecoxib for reducing pain associated with outpatient hysteroscopy: a randomized double-blind placebo-controlled trial.
Topics: Adult; Analgesics, Opioid; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Huma | 2016 |
Tramadol versus Celecoxib for reducing pain associated with outpatient hysteroscopy: a randomized double-blind placebo-controlled trial.
Topics: Adult; Analgesics, Opioid; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Huma | 2016 |
Tramadol versus Celecoxib for reducing pain associated with outpatient hysteroscopy: a randomized double-blind placebo-controlled trial.
Topics: Adult; Analgesics, Opioid; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Huma | 2016 |
Tramadol versus Celecoxib for reducing pain associated with outpatient hysteroscopy: a randomized double-blind placebo-controlled trial.
Topics: Adult; Analgesics, Opioid; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Huma | 2016 |
Tramadol versus Celecoxib for reducing pain associated with outpatient hysteroscopy: a randomized double-blind placebo-controlled trial.
Topics: Adult; Analgesics, Opioid; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Huma | 2016 |
Tramadol versus Celecoxib for reducing pain associated with outpatient hysteroscopy: a randomized double-blind placebo-controlled trial.
Topics: Adult; Analgesics, Opioid; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Huma | 2016 |
Tramadol versus Celecoxib for reducing pain associated with outpatient hysteroscopy: a randomized double-blind placebo-controlled trial.
Topics: Adult; Analgesics, Opioid; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Huma | 2016 |
A randomized, double-blind, positive-controlled, 3-way cross-over human experimental pain study of a TRPV1 antagonist (V116517) in healthy volunteers and comparison with preclinical profile.
Topics: Adolescent; Adult; Aminopyridines; Animals; Capsaicin; Celecoxib; Cross-Over Studies; Cyclooxygenase | 2016 |
Efficacy of celecoxib versus ibuprofen for the treatment of patients with osteoarthritis of the knee: A randomized double-blind, non-inferiority trial.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; C | 2017 |
Potential effects of chondroitin sulfate on joint swelling: a GAIT report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chondroitin Sulfates; Double-Blind Method; Femal | 2008 |
A COX-2 inhibitor reduces muscle soreness, but does not influence recovery and adaptation after eccentric exercise.
Topics: Adaptation, Physiological; Adult; Arm; Celecoxib; Cyclooxygenase 2 Inhibitors; Dinoprostone; Double- | 2010 |
Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: a double-blind, randomized, dose-ranging trial.
Topics: Adult; Aged; Analgesics, Opioid; Celecoxib; Cyclooxygenase 2 Inhibitors; Delayed-Action Preparations | 2011 |
Efficacy of celecoxib, meloxicam and paracetamol in elderly Kashin-Beck disease (KBD) patients.
Topics: Acetaminophen; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Female; | 2011 |
Efficacy of low-dose celecoxib in patients with acute pain.
Topics: Adolescent; Adult; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Double- | 2011 |
A randomized, clinical trial comparing oral celecoxib 200 mg, celecoxib 400 mg, and ibuprofen 600 mg for acute pain.
Topics: Acute Disease; Adult; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double | 2003 |
Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain.
Topics: Aged; Celecoxib; Cyclooxygenase Inhibitors; Female; Health Status; Humans; Lactones; Logistic Models | 2003 |
A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee.
Topics: Adult; Aged; Analysis of Variance; Celecoxib; Double-Blind Method; Female; Humans; Knee; Lactones; M | 2003 |
Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; | 2004 |
[Treatment of osteoarthritis of the knee joint. Efficacy and tolerance to acemetacin slow release in comparison to celecoxib].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Confidence Intervals; Data Interpretation | 2004 |
Therapeutic interchange involving replacement of rofecoxib or celecoxib with valdecoxib.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost Savings; Cyclooxyge | 2004 |
Lumiracoxib.
Topics: Administration, Oral; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Doubl | 2004 |
Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response | 2005 |
Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Celecoxib; C | 2006 |
Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Bl | 2006 |
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chondroitin Sulfates; Double-Blind Method; Drug | 2006 |
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chondroitin Sulfates; Double-Blind Method; Drug | 2006 |
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chondroitin Sulfates; Double-Blind Method; Drug | 2006 |
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chondroitin Sulfates; Double-Blind Method; Drug | 2006 |
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chondroitin Sulfates; Double-Blind Method; Drug | 2006 |
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chondroitin Sulfates; Double-Blind Method; Drug | 2006 |
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chondroitin Sulfates; Double-Blind Method; Drug | 2006 |
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chondroitin Sulfates; Double-Blind Method; Drug | 2006 |
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chondroitin Sulfates; Double-Blind Method; Drug | 2006 |
Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival?
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combi | 2006 |
The efficacy of oral nonsteroidal anti-inflammatory medication (NSAID) in the treatment of plantar fasciitis: a randomized, prospective, placebo-controlled study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Double-Blind Method; Fasciitis, Pla | 2007 |
Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Clematis; Cyclooxy | 2007 |
101 other studies available for celecoxib and Ache
| Article | Year |
|---|---|
3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Chemical Phenomena; Chemi | 2003 |
Synthesis, in vitro, and in vivo biological evaluation and molecular docking simulations of chiral alcohol and ether derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents.
Topics: Acetic Acid; Alcohols; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; | 2008 |
Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Arthritis; Ear; Edema; Female; Freund's Adjuvant; Hyd | 2010 |
Potent and orally efficacious benzothiazole amides as TRPV1 antagonists.
Topics: Amides; Animals; Benzothiazoles; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; I | 2012 |
A class of pyrrole derivatives endowed with analgesic/anti-inflammatory activity.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Cyclooxygenase 2 Inhibitors | 2013 |
Rational design, synthesis and evaluation of chromone-indole and chromone-pyrazole based conjugates: identification of a lead for anti-inflammatory drug.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Capsaicin; Chromones; Cyclooxygenase 1; Cyclooxyge | 2014 |
Synthesis of novel 2-mercaptobenzoxazole based 1,2,3-triazoles as inhibitors of proinflammatory cytokines and suppressors of COX-2 gene expression.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoxazoles; Cyclooxygenase 2; Cycloo | 2014 |
Benzo[d]imidazole Transient Receptor Potential Vanilloid 1 Antagonists for the Treatment of Pain: Discovery of trans-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Mavatrep).
Topics: Analgesics; Animals; Benzimidazoles; Biological Availability; Carrageenan; Dogs; Freund's Adjuvant; | 2015 |
Chemical synthesis and biological evaluation of ω-hydroxy polyunsaturated fatty acids.
Topics: Analgesics; Animals; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Hydroxyeicosatetraenoic Acids; | 2017 |
Synthesis, potential anti-inflammatory and analgesic activities study of (S)-N-substituted-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxamides.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cyclooxygenase 2; Cy | 2017 |
Discovery of {4-[4,9-bis(ethyloxy)-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-2-fluorophenyl}acetic acid (GSK726701A), a novel EP
Topics: Animals; Anti-Inflammatory Agents; Blood Cells; Dinoprostone; Drug Evaluation, Preclinical; Half-Lif | 2018 |
Tailoring the Substitution Pattern on 1,3,5-Triazine for Targeting Cyclooxygenase-2: Discovery and Structure-Activity Relationship of Triazine-4-Aminophenylmorpholin-3-one Hybrids that Reverse Algesia and Inflammation in Swiss Albino Mice.
Topics: Analgesics; Animals; Carrageenan; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Design; Drug D | 2018 |
Molecular docking and synthesis of caffeic acid analogous and its anti-inflammatory, analgesic and ulcerogenic studies.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caffeic Acids; Carrageena | 2021 |
Synthesis and biological evaluation of new series of benzamide derivatives containing urea moiety as sEH inhibitors.
Topics: Animals; Benzamides; Enzyme Inhibitors; Epoxide Hydrolases; Pain; Rats; Structure-Activity Relations | 2022 |
Tramadol/celecoxib (Seglentis) for pain.
Topics: Analgesics, Opioid; Celecoxib; Humans; Hydrocodone; Oxycodone; Pain; Pain, Postoperative; Tramadol | 2022 |
Quantitative Spectrophotometric Analysis of Celecoxib and Tramadol in Their Multimodal Analgesia Combination Tablets.
Topics: Adult; Analgesia; Analgesics, Opioid; Celecoxib; Humans; Pain; Pain Management; Tablets; Tramadol | 2022 |
Novel Formulation Approaches used for the Management of Osteoarthritis: A Recent Review.
Topics: Animals; Celecoxib; Female; Hydrogels; Male; Osteoarthritis; Pain; Rats; Rats, Inbred Lew | 2023 |
Inhibition of PGE2 in Subchondral Bone Attenuates Osteoarthritis.
Topics: Animals; Capsaicin; Cartilage, Articular; Celecoxib; Dinoprostone; Humans; Mice; Mice, Knockout; Ost | 2022 |
[Effects of acupotomy on partial movement gait and serum tumor necrosis factor-α, interleukin-1β in patients with knee osteoarthritis].
Topics: Acupuncture Therapy; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Female; Gait; Humans; | 2022 |
Green micelle and complex inclusion enhance synchronous spectrofluorimetric quantification of a novel analgesic combination: Tramadol and celecoxib in tablet dosage form and spiked human plasma.
Topics: Analgesics; Celecoxib; Humans; Micelles; Pain; Spectrometry, Fluorescence; Tablets; Tramadol | 2023 |
Operating without opioids.
Topics: Acetaminophen; Analgesics; Analgesics, Opioid; Celecoxib; Drug Combinations; Drug Prescriptions; Gen | 2019 |
Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease.
Topics: Amidohydrolases; Analgesics; Animals; Benzamides; Brain; Cannabidiol; Capsaicin; Carbamates; Celecox | 2020 |
Antinociceptive and anti-inflammatory effects of 4-(arylchalcogenyl)-1H-pyrazoles containing selenium or sulfur.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Celecoxib; Disease Models, Animal; Dose-Response Rela | 2020 |
Sex Differences Revealed in a Mouse CFA Inflammation Model with Macrophage Targeted Nanotheranostics.
Topics: Adjuvants, Immunologic; Administration, Intravenous; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxyg | 2020 |
Anti-inflammatory and analgesic effect of LD-RT and some novel thiadiazole derivatives through COX-2 inhibition.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Celecoxib; Combined Modality Therapy; Cyclooxygenase | 2020 |
Antinociception produced by nonsteroidal anti-inflammatory drugs in female vs male rats.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Disease Models, Animal; Dos | 2021 |
Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy-Lysosomal Pathway.
Topics: Animals; Arthritis, Experimental; Celecoxib; Chondrocytes; Diabetes Mellitus, Type 2; Disease Models | 2021 |
The effective interplay of (non-) selective NSAIDs with neostigmine in animal models of analgesia and inflammation.
Topics: Acetic Acid; Analgesia; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Dic | 2021 |
Fixed-dose combination amlodipine-celecoxib for treatment of hypertension and osteoarthritis pain: an up-to-date evaluation.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Celecoxib; Drug Combinations; Humans; Hypertens | 2021 |
The Analgesic Effects of Celecoxib on the Formalin-induced Short- and Long-term Inflammatory Pain.
Topics: Analgesics; Animals; Celecoxib; Dose-Response Relationship, Drug; Formaldehyde; Hyperalgesia; Male; | 2017 |
NSAIDs relieve osteoarthritis (OA) pain, but cardiovascular safety in question even for diclofenac, ibuprofen, naproxen, and celecoxib: what are the alternatives?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Humans; Ibuprofen; Naproxen; Network | 2017 |
Effective treatment of aggressive fibromatosis with celecoxib guided by genetic testing.
Topics: Adult; beta Catenin; Biopsy; Celecoxib; Cyclooxygenase 2 Inhibitors; Fibromatosis, Aggressive; Genet | 2017 |
Kartogenin inhibits pain behavior, chondrocyte inflammation, and attenuates osteoarthritis progression in mice through induction of IL-10.
Topics: Anilides; Animals; Cartilage; Cartilage, Articular; Celecoxib; Chondrocytes; Chondrogenesis; Cytokin | 2018 |
Contribution of synovial macrophages to rat advanced osteoarthritis pain resistant to cyclooxygenase inhibitors.
Topics: Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Dinoprostone; Disease | 2019 |
Factors affecting the results of analgesic therapy. Results of the Russian multicentre study of NOTE (NSAID: Open-label Trial of Efficacy).
Topics: Adult; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Female; Hum | 2018 |
Evidence for antinociceptive effects of combined administration of vitamin E and celecoxib in tail-flick and formalin test in male rats.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Formaldehyde; Indomethacin; | 2019 |
NSAID choice: lessons from PRECISION.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Humans; Ibuprofen; Napr | 2019 |
More pain for painkillers.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase | 2013 |
Antihyperalgesic/antinociceptive effects of ceftriaxone and its synergistic interactions with different analgesics in inflammatory pain in rodents.
Topics: Acetaminophen; Analgesics; Analgesics, Non-Narcotic; Animals; Anti-Bacterial Agents; Ceftriaxone; Ce | 2014 |
Antinociceptive effect of 3-(4-fluorophenyl)-5-trifluoromethyl-1H-1-tosylpyrazole. A Celecoxib structural analog in models of pathological pain.
Topics: Analgesics; Animals; Celecoxib; Disease Models, Animal; Male; Mice; Pain; Pyrazoles; Sulfonamides; T | 2014 |
Intra-articular (IA) ropivacaine microparticle suspensions reduce pain, inflammation, cytokine, and substance p levels significantly more than oral or IA celecoxib in a rat model of arthritis.
Topics: Administration, Oral; Amides; Animals; Arthritis, Experimental; Celecoxib; Cytokines; Inflammation; | 2015 |
Complete Freund's adjuvant-induced reduction of exploratory activity in a novel environment as an objective nociceptive endpoint for sub-acute inflammatory pain model in rats.
Topics: Adjuvants, Immunologic; Amines; Analgesics; Animals; Behavior, Animal; Celecoxib; Cyclohexanecarboxy | 2015 |
The cancer pain related factors affected by celecoxib together with cetuximab in head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cell Survival; Cetuxim | 2015 |
[Treatment of Knee Osteoarthritis by Tendons of Minimally Invasive Therapy Combined Drug Ther- apy: a Clinical Observation of Sixty Cases].
Topics: Celecoxib; Drug Therapy, Combination; Humans; Knee Joint; Osteoarthritis, Knee; Pain; Pain Measureme | 2015 |
Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Com | 2016 |
Pharmacological characterization of intraplantar Complete Freund's Adjuvant-induced burrowing deficits.
Topics: Amines; Analgesics; Animals; Antibodies; Behavior, Animal; Celecoxib; Cyclohexanecarboxylic Acids; D | 2016 |
Involvement of subcellular organelles in inflammatory pain-induced oxidative stress and apoptosis in the rat hepatocytes.
Topics: Animals; Apoptosis; Aspirin; Celecoxib; Hepatocytes; Inflammation; Male; Organelles; Oxidative Stres | 2008 |
The NIH Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT).
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chondroitin Sulf | 2008 |
The analgesic actions of centrally administered celecoxib are mediated by endogenous opioids.
Topics: Analgesics, Opioid; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carragee | 2009 |
Etodolac attenuates mechanical allodynia in a mouse model of neuropathic pain.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Cyclooxygenase 2 Inhibitor | 2009 |
Kaposiform hemangioendothelioma in multiple spinal levels without skin changes.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers, Tumor; Celecoxib; Chil | 2009 |
Comparison of mechanical allodynia and the affective component of inflammatory pain in rats.
Topics: Analgesics, Non-Narcotic; Animals; Behavior, Animal; Celecoxib; Central Nervous System Agents; Diclo | 2010 |
Effect of celecoxib on emotional stress and pain-related behaviors evoked by experimental tooth movement in the rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Biomechanical Phenomena; Celecox | 2009 |
Guaifenesin enhances the analgesic potency of ibuprofen, nimesulide and celecoxib in mice.
Topics: Acetic Acid; Analgesia; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cele | 2009 |
Is the sulphonamide radical in the celecoxib molecule essential for its analgesic activity?
Topics: Acetazolamide; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationsh | 2010 |
The analgesic and anti-inflammatory effect of WIN-34B, a new herbal formula for osteoarthritis composed of Lonicera japonica Thunb and Anemarrhena asphodeloides BUNGE in vivo.
Topics: Analgesics; Anemarrhena; Animals; Anti-Inflammatory Agents; Behavior, Animal; Capillary Permeability | 2010 |
Gait analysis and pain response of two rodent models of osteoarthritis.
Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Gait; Male; Neuropeptides; | 2011 |
Microsomal prostaglandin E synthase-1 enhances bone cancer growth and bone cancer-related pain behaviors in mice.
Topics: Animals; Behavior, Animal; Bone Neoplasms; Calcitonin Gene-Related Peptide; Carcinoma, Lewis Lung; C | 2011 |
Codeine did not increase analgesic efficacy of coxibs in contrast to that of paracetamol or ibuprofen: isobolographic analysis in mice.
Topics: Acetaminophen; Acetic Acid; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Celecoxib; Codein | 2011 |
Endogenous opioid and cannabinoid mechanisms are involved in the analgesic effects of celecoxib in the central nervous system.
Topics: Analgesics; Animals; Carrageenan; Celecoxib; Central Nervous System; Cyclooxygenase 2; Cyclooxygenas | 2012 |
Pharmacological modulation of brain activity in a preclinical model of osteoarthritis.
Topics: Action Potentials; Animals; Brain; Celecoxib; Disease Models, Animal; Humans; Male; Nerve Net; Osteo | 2013 |
Intra-articular delivery of liposomal celecoxib-hyaluronate combination for the treatment of osteoarthritis in rabbit model.
Topics: Animals; Arthritis, Experimental; Cartilage, Articular; Celecoxib; Cyclooxygenase 2 Inhibitors; Gels | 2013 |
Taurine enhances antinociception produced by a COX-2 inhibitor in an inflammatory pain model.
Topics: Analgesics; Animals; Carrageenan; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Synergism; Drug Thera | 2013 |
Augmented chondroprotective effect of coadministration of celecoxib and rebamipide in the monosodium iodoacetate rat model of osteoarthritis.
Topics: Administration, Oral; Alanine; Animals; Arthritis, Experimental; Behavior, Animal; Cartilage; Celeco | 2013 |
Celecoxib treatment does not alter recruitment and activation of osteoclasts in the initial phase of experimental tooth movement.
Topics: Animals; Bone Resorption; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Models, Animal; | 2012 |
Celecoxib, safe in NSAID intolerance.
Topics: Administration, Oral; Adult; Aged; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; C | 2002 |
The AGS' fondness for celecoxib.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Geriatrics; Humans; Pain; Pyrazoles; Socie | 2002 |
[Adverse effect-free analgesia. New COX-2 inhibitor is even more selective].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2003 |
Nonsteroidal anti-inflammatory drugs increase expression of inducible COX-2 isoform of cyclooxygenase in spinal cord of rats with adjuvant induced inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhi | 2004 |
Hypertension associated with therapies to treat arthritis and pain.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agent | 2004 |
Involvement of spinal neurokinins, excitatory amino acids, proinflammatory cytokines, nitric oxide and prostanoids in pain facilitation induced by Phoneutria nigriventer spider venom.
Topics: Animals; Antibodies; Calcitonin Gene-Related Peptide Receptor Antagonists; Celecoxib; Citrates; Cycl | 2004 |
Development and pharmacological characterization of a rat model of osteoarthritis pain.
Topics: Alkylating Agents; Analgesics, Opioid; Animals; Celecoxib; Cyclooxygenase Inhibitors; Disease Models | 2005 |
Effect of celecoxib, a cyclooxygenase-2 inhibitor, on the pathophysiology of adjuvant arthritis in rat.
Topics: Animals; Arthritis, Experimental; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxy | 2005 |
Prostanoids as friends, not foes: further evidence from the interference by cycloxygenase-inhibitory drugs when inducing tolerance to experimental arthritigens in rats.
Topics: Administration, Oral; Animals; Arthritis, Experimental; Aspirin; Celecoxib; Cyclooxygenase 2; Cycloo | 2005 |
Celecoxib approved for pain relief for AS.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Humans; Pain; Pyrazoles; Spondylitis, Ankylosing | 2005 |
Analgesic effects of intrathecally administered celecoxib, a cyclooxygenase-2 inhibitor, in the tail flick test and the formalin test in rats.
Topics: Analgesia; Analysis of Variance; Animals; Behavior, Animal; Celecoxib; Cyclooxygenase 2 Inhibitors; | 2006 |
Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis--a population-based survey.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; | 2006 |
Arthritis supplement combination falls short in study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chondroitin Sulfates; Clinical Trials as Topic; | 2006 |
Additive interaction of intraperitoneal dexmedetomidine and topical nimesulide, celecoxib, and DFU for antinociception.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; | 2007 |
Use of celecoxib immediately post marketing in Canada: acute or chronic pain?
Topics: Acute Disease; Adult; Aged; Canada; Celecoxib; Chronic Disease; Cyclooxygenase 2 Inhibitors; Diffusi | 2007 |
Celecoxib inhibits Na+ currents in rat dorsal root ganglion neurons.
Topics: Animals; Animals, Newborn; Celecoxib; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase Inhibitors; | 2007 |
Eosinophilic fasciitis in a 57-year-old Japanese-American woman.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diagnosis, Differential; Eosinophilia; Fasciitis | 2007 |
Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA.
Topics: Animals; Carrageenan; Celecoxib; Chlorobenzoates; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Din | 2008 |
COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia.
Topics: Analgesia; Analgesics, Opioid; Analysis of Variance; Animals; Behavior, Animal; Blotting, Western; C | 2007 |
Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade.
Topics: Animals; Arthritis; Astrocytes; Behavior, Animal; Celecoxib; Collagen; Cyclooxygenase Inhibitors; Di | 2007 |
The effects of intrathecal cyclooxygenase-1, cyclooxygenase-2, or nonselective inhibitors on pain behavior and spinal Fos-like immunoreactivity.
Topics: Animals; Behavior, Animal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitor | 2008 |
Outfoxing pathways of pain. 'COX-2' drugs are easier on stomach.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase Inhibitors; Drug Appro | 1998 |
What did you say? I can't quite understand your spoken order.
Topics: Antidepressive Agents, Second-Generation; Arthritis; Celecoxib; Citalopram; Cyclooxygenase Inhibitor | 1999 |
[Gastric protective pain therapy. What is the advantage of new COX-2 inhibitors?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2000 |
Acute onset of auditory hallucinations after initiation of celecoxib therapy.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; | 2000 |
COX-2 inhibitors and Celebrex: safe or suspect?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 In | 1999 |
Cyclooxygenase-2 inhibition and renal function.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Burns, Chemical; Celecoxib; Cyclooxygenase 2; Diuresis; Fem | 2001 |
[Role of cyclooxygenase-2 (COG-2) in the etiology of pain].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibit | 2001 |
Pain relief at a price. A blow to the heart?
Topics: Arthritis; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; | 2001 |
Arthritis: what it is, why you get it and how to stop the pain.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement; Celecoxib; Cyclooxy | 2001 |
Effects of selective COX-1 and -2 inhibition on formalin-evoked nociceptive behaviour and prostaglandin E(2) release in the spinal cord.
Topics: Animals; Behavior, Animal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitor | 2001 |
Pain treatment with NSAIDs, primary focus on ibuprofen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Humans; Ibuprofen; Pa | 2001 |
Participation of COX, IL-1 beta and TNF alpha in formalin-induced inflammatory pain.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Blocking; Celecoxib; Cyclooxygenase In | 2001 |
The role of cyclooxygenase-1 and -2 in the rat formalin test.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 1; | 2002 |
A rat model of bone cancer pain.
Topics: Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Body Tempera | 2002 |
Comparison of the antinociceptive effect of celecoxib, diclofenac and resveratrol in the formalin test.
Topics: Analgesia; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Celecoxib; Cyclooxyge | 2002 |